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Targeted chemotherapy has been a challenge in Nanomedicine. Nanoparticles (NPs) of 
biodegradable polymers can serve as effective drug delivery systems to carry the 
chemotherapeutic agents to cancer cells. These drug delivery systems can be further 
functionalized with targeting ligands which can bind to specific receptors 
overexpressing on the surface of cancer cells, thus achieving highly-specific targeting 
function. This work developed two novel drug delivery systems of trastuzumab-
decorated nanoparticles (NPs) of biodegradable polymers for targeted chemotherapy 
with Taxoids (Paclitaxel and Docetaxel) as model small molecule therapeutics. 
Trastuzumab (Herceptin®) is a FDA-approved humanized monoclonal antibody drug 
which is effective for the cancer of human epidermal growth factor receptor-2 (HER2) 
overexpression. It is also found synergistic with Taxoids.  
 
The first system is paclitaxel-loaded poly(D,L-lactide-co-glycolide)/montmorillonite 
(PLGA/MMT) NPs with trastuzumab physically adhered on the NP surface. The NPs 
were prepared by a modified solvent extraction/evaporation method and characterized 
by state-of-the art equipment for their physicochemical and pharmaceutical properties 
such as size and size distribution, surface morphology, surface chemistry, surface 
charge, drug encapsulation efficiency and in vitro drug release kinetics. Both of the 
quantitative and qualitative investigation showed that the paclitaxel-loaded 
PLGA/MMT NPs with trastuzumab-decoration achieved significantly higher cellular 
uptake efficiency than the NPs without trastuzumab-decoration. The results of in vitro 
cytotoxicity experiment on SK-BR-3 cells further proved the targeting effects of 
trastuzumab decoration on the PLGA/MMT nanoparticles. Judged by IC50 of SK-BR-
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3 cells after 24 h culture, the therapeutic effects of the Pac-PLGA/MMT-HER NP 
formulation could be 12.74 times higher than that of the Pac-PLGA/MMT NP 
formulation and 13.11 times higher than Taxol®. 
 
The second system is the docetaxel-loaded NPs of a blend of two novel copolymers. 
One is poly(lactide)-D-α-tocopheryl polyethylene glycol succinate (PLA-TPGS), 
which is of ideal hydrophobic-lipophilic balance for high drug encapsulation efficiency 
and high cellular adhesion, and another is carboxyl group-terminated TPGS (TPGS-
COOH), which facilitates the antibody  conjugation on the nanoparticle surface. The 
targeting effect can be quantitatively controlled by adjusting the copolymer blend ratio, 
which was testified by in vitro viability experiments on SK-BR-3 cells and MCF-7 
cells. Judged by cellular mortality, the trastuzumab-functionalized NP formulation can 
be 1.215-, 1.215- and 1.073-fold more effective for MCF-7 cells, and 1.697-, 1.886- 
and 1.126-fold more effective for SK-BR-3 cells than the NP formulation without 
trastuzumab-functionalization after 24, 48 and 72 h treatment, respectively. The 
trastuzumab-functionalized NPs have great potential to be applied as targeted 
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Chapter 1 Introduction 
1.1 Background 
In recent years, studies on design and synthesis of nanoparticles (NPs) of biodegradable 
polymers that are suitable for biomedical applications have attracted great interest. Drug-
loaded NPs have considerable potential to provide an ideal solution for the major 
problems encountered in chemotherapy. The advantages of nanoparticles-based drug 
delivery systems include the sustained drug release, reduced systemic side effects, and 
high capability to cross various physiological barriers (Graduspizlo et al., 1995; Feng & 
Chien, 2003; Mu & Feng, 2003). However, low selectivity of NPs towards the cancer cells 
hinders the advantages of the nanoparticle formulation for efficient chemotherapy. It is 
essential to increase the specificity of the drugs-loaded NPs to the cancer cells so as to 
deliver the therapeutic agent to the targeted cells, thus improving the therapeutic efficacy 
and reducing side effects. 
 
Progression of cancer is often accompanied by the overexpression of certain special 
proteins called tumor antigens, which can be used as biomarkers to differentiate the cancer 
cells from the healthy cells for development of targeting strategy. The key is to identify 
the ideal ligand from phage libraries (Becerril et al., 1999). Among various antigens 
present on malignant cells, human epidermal growth factor receptor-2 (HER2) has been 
used most often in the literature as a biomarker for targeted drug delivery to HER2 
overexpressing breast cancer cells, which is notable for its role in the pathogenesis of 
breast cancer (Kraus et al., 1989; Olayioye, 2001; Shukla et al., 2006; Cirstoiu-Hapca et 
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al., 2007). HER2 is a cell membrane surface-bound receptor tyrosine kinase and is 
normally involved in the signal transduction pathways leading to cell growth, survival, 
and differentiation in a complex manner. It has been found that 25-30% breast cancers 
have amplification of HER2 gene or overexpression of its protein product, which is 
associated with increased recurrence and worse prognosis of the cancer (Slamon et al., 
1989; Baselga et al., 1998; Neve et al., 2001). 
 
Trastuzumab is a humanized monoclonal antibody (mAb) directed against the HER2 
epitope, which increases the clinical benefit of first-line chemotherapy in patients with 
metastatic breast cancers that overexpress HER2 (Albanell & Baselga, 1999; Plosker & 
Keam, 2006). Trastuzumab was the first HER2-targeted therapy approved by the United 
States Food and Drug Administration (FDA) for the treatment of metastatic breast cancer 
(MBC), either as a single agent or in the first-line setting in combination with 
chemotherapy (McKeage & Perry, 2002). Moreover, trastuzumab has been found to 
posses synergistic effects with small molecule anticancer drugs such as paclitaxel, 
docetaxel, gemcitabine, etc (Slamon et al., 2001; Romond et al., 2005; Coudert et al., 
2006; Hussain et al., 2007). Therefore, the combination of trastuzumab and small 
molecule anticancer drugs for the treatment of HER2 overexpressed breast cancer has 
been suggested as a promising means of targeted chemotherapy. 
 
1.2 Objective 
The objective of this research is to study the effectiveness of two systems of trastuzumab-
functionalized nanoparticles for targeted drug delivery. In the first part, a novel system of 
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trastuzumab-decorated poly(D,L-lactide-co-glycolide/montmorillonite (PLGA/MMT) NPs 
was developed for targeted delivery of paclitaxel. In the second part, a strategy to 
quantitatively control the targeting effect was developed, in which NPs were consisted of 
a blend of two-component copolymers. One is poly(lactide)-D-α-tocopheryl polyethylene 
glycol succinate (PLA-TPGS), which is of desired hydrophobic-lipophilic balance (HLB) 
and therefore can result in high drug encapsulation efficiency and high cellular 
adhesion/adsorption. Another is carboxyl group-terminated TPGS (TPGS-COOH), which 
facilitates the conjugation of trastuzumab on NP surface for targeted drug delivery. 
Experiments were carried out to investigate the feasibility of the obtained NPs for targeted 
delivery of small molecule drugs. The trastuzumab conjugated on nanoparticle surface has 
two functions: one is to target HER2-overexpressing cancer cells, and the other is to 
enhance the cytotoxicity of encapsulated drug through synergistic effects to kill cancer 
cells. The trastuzumab-functionalized NPs have great potential to be applied as targeted 
therapeutics against the HER2-overexpressing cancer. 
 
1.3 Thesis organization 
The thesis is made up of five chapters. Chapter 1 gives a brief introduction to the project. 
Chapter 2 is a literature review on nanotechnologies in cancer chemotherapy.  In chapter 3, 
study on paclitaxel-loaded PLGA/MMT NPs, which were further decorated with 
trastuzumab through physical adhesion for targeted chemotherapy was reported. Chapter 4 
describes the study of docetaxel-loaded NPs consisted of a blend of two-component 
copolymers, poly(lactide)-D-α-tocopheryl polyethylene glycol succinate (PLA-TPGS), 
which is of desired hydrophobic-lipophilic balance (HLB), and carboxyl group-terminated 
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D-α-tocopheryl polyethylene glycol succinate (TPGS-COOH), which facilitates the 
conjugation of trastuzumab on the NP surface for targeting. Lastly, conclusions and 
recommendations are presented in Chapter 5 to promote the further application of 
trastuzumab-functionalized nanoparticles of biodegradable polymers for targeted 
chemotherapy.  
 5
Chapter 2 Literature review 
2.1 Cancer 
2.1.1 Introduction to cancer 
Cancer is a class of diseases in which abnormal cells divide without control and are able to 
invade other tissues. Cancers are usually developed in the form of tumors. There are two 
main types of tumors, benign tumors and malignant tumors. Benign tumors do not spread 
to other parts of the body. They are localized in one part of the body and are not life-
threatening. Malignant tumors can spread from the original site of cancer to other tissues, 
which process is called “Metastasis” (Liotta et al., 1991).  
 
Cancer can seriously threaten human health and is a leading cause of death in the world 
(Feng & Chien, 2003). Every year, nearly 1.4 million people in North America are 
diagnosed with cancer. In 2009, about 562,340 Americans are expected to die of cancer, 
more than 1,500 people a day. Cancer is the second most common cause of death in the 
US, exceeded only by heart disease. In the US, cancer accounts for nearly 1 of every 4 
deaths (American Cancer Society Statistics for 2009). 
 
2.1.2 Causes of cancer 
Though the mechanisms of formation and spreading of cancers are still not well 
understood, cancers are caused by many factors mainly divided into both internal and 
external factors. Internal factors include inherited metabolism mutations, immune 
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conditions and hormones. External factors refer to smoking, chemicals, infections and 
radiation. It is suspected that up to 80 percent of all cancers are related to the use of 
tobacco products. Smokers have a higher risk of developing larynx, pancreas, bladder, 
kidney, cervix, and lung cancers (Hecht, 1999). The type of food and drinks that we 
consume can also affect the risk of contracting cancer, e.g. high-fat diet is linked to the 
breast, colon, uterus and prostate cancer. Moreover, over consumption of alcohol may 
increase the risk of liver, mouth and throat cancers. Both internal and external factors may 
work together to initiate and promote carcinogenesis. It usually takes years from the initial 
cell mutation to the formation of detectable cancer.  
 
There is clear evidence that the incidence of cancer can be reduced by: (1) appropriate 
nutrition and regular physical activity, (2) controlled tobacco, alcohol usage, obesity and 
sun exposure, (3) regular cancer screening (Thompson et al., 2004). 
 
2.1.3 Cancer treatments 
Effective cancer treatments include surgery, chemotherapy, radiation therapy, hormonal 
therapy, targeted therapy or other methods. As cancer refers to a class of diseases, one or 
more treatment modalities may be used to provide the most effective treatment. Choice of 
cancer treatment is often influenced by several factors, including the specific 
characteristics of the cancer: location and grade of the cancer; the overall condition of 
patients and the stage of the disease; and whether the goal of treatment is to cure the 
cancer, keep the cancer from spreading, or to relieve the symptoms caused by cancer 
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(Ceelen et al., 2000). It is common to use several treatment modalities concurrently or in 
sequence with the goal of preventing recurrence. 
 
To completely remove the cancer without damage to the rest of the body is the goal of 
treatment. Nearly all patients with cancer will have some kind of surgery. Surgery may be 
used to perform a biopsy in order to obtain a specimen for determining an accurate 
diagnosis, provide local treatment of the cancer, and obtain other information to help 
determine whether additional treatment is necessary. Surgical techniques continue to 
improve, and surgeries are now less invasive and often performed on an outpatient basis. 
However, if the propensity of cancers invades adjacent tissue or spreads to distant sites by 
microscopic metastasis, it is difficult for surgery to be performed (Bokemeyer et al., 2007). 
Moreover, it is usually unavoidable to have residual affected cells, which limits the 
effectiveness of surgery. Therefore, many cancers are treated with surgery and a 
combination of chemotherapy and/or radiotherapy.  
 
Radiotherapy employs high-energy ionizing rays to kill cancer cells and shrink tumors by 
damaging the DNA in the cancer cell, thereby disabling the cancer cells from reproducing 
and growing. Although normal tissues may be affected by the radiation, they can generally 
recover. Radiotherapy is a targeted cancer treatment like surgery, so this treatment is not 
effective to patients whose cancer cells have started to spread to other parts of their body 
(Geh et al., 2006). Nonetheless, there are many side effects associated with radiotherapy. 
For example, patients may feel tired, loss of appetite and develop skin reactions during the 
treatment period. Like many cancer treatments, some side effects are associated with 
hormone therapy such as nausea, swelling of limbs and weight gain. Women may 
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experience hot flushes, irregular periods or vaginal dryness, while men may become 
impotence or lack of sexual desire. All of these symptoms are results of change in 
hormonal balance in the body because of hormone therapy. Chemotherapy was developed 
in the 1950s and widely applied until the 1960s. Chemotherapy combined with some other 
treatments has been a primary method in cancer treatment (Schally & Nage, 1999). 
Especially, in recent ten years, nanotechnology has been developed and widely 
investigated in cancer chemotherapy and it may promote new concept chemotherapy and 
cancer chemotherapy at home (Feng & Chien, 2003). 
 
Targeted cancer therapies use drugs that block the growth and spread of cancer, which 
interfere with specific molecules involved in carcinogenesis and tumor growth. Targeted 
cancer therapies are sometimes called “molecular-targeted drugs” as the molecules have 
targeting function (Kolonin et al., 2001; Schwartz & Shah, 2005). Targeted cancer 
therapies interfere with cancer cell growth and division in different ways and at various 
points during the development, growth, and spread of cancer. Many of these therapies 
focus on proteins that are involved in the signaling process. By blocking the signals that 
tell cancer cells to grow and divide uncontrollably, targeted cancer therapies can help to 
stop the growth and division of cancer cells. With focus on molecular and cellular changes 
that are specific to cancer, targeted cancer therapies may be more effective than current 
treatments and less harmful to normal cells. 
 
Hormone therapy is the use of hormones in medical treatment and it is one of the major 
modalities of medical treatment for cancer, others being cytotoxic chemotherapy and 
targeted therapy. It involves the manipulation of the endocrine system through exogenous 
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administration of specific hormones, particularly steroid hormones, or drugs which inhibit 
the production or activity of such hormones (Schally & Nagy, 2004). 
 
2.2 Cancer chemotherapy 
2.2.1 Chemotherapy 
Chemotherapy, in its most general sense, is defined as the use of any medicine for 
treatment of any disease. Specifically for the case of cancer, chemotherapy is understood 
in a narrower sense of using chemotherapeutic agents to kill or to control the cancer cells 
(Slamon et al., 2001). This method gained popularity in the 1970s as a means to cure 
certain types of cancers or at the least, lengthen the life expectancy of patients. 
Chemotherapy is a major therapeutic approach for the treatment of localized and 
metastasized cancers. 
 
These drugs are often called anticancer drugs. Anticancer drug can inhibit the uncontrolled 
growth and multiplying of cancer cells. Some drugs can work together better than alone 
and thus two or more drugs may be used in chemotherapy to get the synergistic effect, 
which is called combination chemotherapy (Gregory et al., 1992). Chemotherapy can be 
used to cure cancers in different ways which depends on the types of cancer and how 
advanced it is. It can relieve symptoms such as pain caused by the cancer which can 
improve the life quality of patients. Chemotherapy can also be used to control the cancer 
by keeping the cancer from spreading, inhibiting its growth or killing cancer cells.  
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Cancer chemotherapy may consist of single drug or combination of drugs, and can be 
administered through a vein, injected into a body cavity, or delivered orally in the form of 
a pill. Chemotherapy is different from surgery or radiation therapy in that the cancer-
fighting drugs circulate in the blood to parts of the body where the cancer may have 
spread and can kill or eliminate cancers cells at sites great distances from the original 
cancer. As a result, chemotherapy is considered a systemic treatment. 
 
More than half of all people diagnosed with cancer receive chemotherapy.  For millions of 
people who have cancers that respond well to chemotherapy, this approach helps treat 
their cancer effectively. However, many side effects associated with chemotherapy are 
still not easy to be prevented or controlled, preventing many people from working, 
travelling, and participating in many of their other normal activities while receiving 
chemotherapy (Momparler, 1980; ten Tije et al., 2003). There have been so far hundreds 
of anticancer agents available for clinical use; some are synthetic chemicals and some are 
natural extracts. Combination of chemotherapy with other treatments has become the 
primary and standard treatments for cancers, as well as for other diseases caused by 
uncontrolled cell growth and invasion of foreign cells or viruses (Hall et al., 2003; Kim & 
Kim, 2009). 
 
2.2.2 Problems in chemotherapy 
Chemotherapy is a complicated procedure in which the chemotherapeutic agent is decisive 
to the success of cancer chemotherapy. More toxic drugs usually produce better 
therapeutic effects but also lead to the side effects which can affect the life quality of 
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patients and prevent the effectiveness of chemotherapy.  Anticancer drugs not only affect 
the cancer cells, but also inhibit certain normal cells from multiplying quickly, such as 
blood cells formed in the bone marrow and cells in the digestive tract (mouth, stomach, 
intestines, esophagus), reproductive system (sexual organs), and hair follicles. Some 
anticancer drugs may affect cells of vital organs such as the heart, kidney, bladder, lungs, 
and nervous system (Feng & Chien, 2003). 
 
2.2.2.1 Toxicity 
A major drawback for chemotherapy is that the chemotherapeutic agents not only kill the 
cancer cells, but also have an effect on the normal healthy cells as well. As the 
chemotherapeutic agents are highly toxic, administration of these agents brings about 
undesirable side effects to the patients undergoing chemotherapy, thus disturbing the 
quality of life for these patients (Jordan & Carmo-Fonseca, 2000; Bosch et al., 2006). 
Organs such as the liver and kidney which are important in excretion and metabolism may 
inevitably be damaged by the chemotherapeutic agents (Lokiec, 2007). This provides a 
motivation for developing drug delivery systems with targeting functions such that the 
chemotherapeutic agents only affect the cancer cells and leave the healthy cells unaffected. 
 
2.2.2.2 Dosage form 
Dosage form of the chemotherapeutic agent is one main problem in chemotherapy (Frei & 
Canellos, 1980). As most anticancer drugs are hydrophobic, they in general have very low 
solubility in water and most pharmaceutical solvents. As a result, the conventional method 
of preparing the treatment is by using an adjuvant as a carrier to deliver the anticancer 
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drug throughout the body. Available adjuvants used for clinical administration are 




Certain anticancer drugs would bind more specifically to some tissues or proteins due to 
the physicochemical nature of the drugs, resulting in a low drug concentration at the 
cancerous cells. This leads to low efficacy of drug delivery, unsatisfactory therapeutic 
effect and even accumulation of toxins in the body as clinical administration should 
ensure sufficiently long exposure duration of the chemotherapeutic drugs to the cancerous 
cells as well as at an appropriate concentration (Nieto & Vaughan, 2004). Moreover, the 
initial burst from the drug delivery may lead to severe toxicity. A sustained exposure to a 
moderate concentration would be preferred than a pulsed delivery at high concentration. 
On the other hand, fluctuations in the drug concentration may also reduce the reliability of 
the chemotherapy treatment. 
 
2.2.2.4 Drug resistance 
The drug resistance by the physiological system of the human body poses as another 
obstacle to effective drug administration. P-glycoprotein (P-gp), a glycoprotein found in 
the cell membrane, has been found diminish therapeutic effects by to exporting most 
chemotherapeutic agents out of the cells and thus, decreasing antitumor activity (DeMario 
& Ratain, 1998). This protein has been found to be expressed in tissue systems in the liver, 
kidney, colon, small intestines as well as uterine epithelium (Mansouri et al., 1994). 
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Metabolizing isozymes such as cytochrome P450 and phagocytes (mainly expressed in the 
reticuloendothelial system) have also been reported to create susceptible barriers for the 
chemotherapeutic agents from effective drug administration. 
 
Discovering new drugs may require extensive time and much more expensive than 
modifying the delivery system of the existing anticancer drug formulation to increase its 
therapeutic efficacy and effectiveness. In the development of a new concept in 
chemotherapy, an ingenious approach in chemotherapeutic engineering, by modifying the 
delivery technique of drugs more effectively into the body system for treatment had been 
developed. This maybe a more feasible approach as compared to the researching and 
discovering total new anticancer drugs in order to evade the problems faced by the current 
chemotherapy treatment as mentioned. 
 
2.2.3 Anticancer drugs 
Anticancer drugs, otherwise known as antineoplastic agents, are drugs used in the 
treatment of cancer. The available anticancer drugs have distinct mechanisms of action 
and effects on different types of cancer cells. Some well-known examples include 
fluorouracil, methotrexate, doxorubicin and Taxoids (paclitaxel and docetaxel).  
 
2.2.3.1 Paclitaxel 
Paclitaxel is one of the most widely used and effective anticancer drugs. It was isolated 
from the bark extracts of the Pacific Yew tree, Taxus brevifolia in the 1960s (Wani et al., 
1971). Paclitaxel has been detected anti-tumor activity in 1967 and is the prototypical 
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member of the taxane family. The clinical spectrum of paclitaxel is wide, with proven 
roles in the treatment of breast cancer (Holmes et al., 1991; Valero et al., 1995),  lung 
cancer (Ranson et al., 2000), head and neck cancer (Vokes et al., 2003), and ovarian 
cancer (Lopes et al., 1993). Less common cancers, such as endometrial, unknown primary, 
testes, esophageal, and Kaposi's sarcoma, also have meaningful response rates to 
paclitaxel either alone or in combination with other agents (Spencer & Faulds, 1994; 
Rowinsky& Donehower, 1995). 
 
The molecular structure of paclitaxel is shown in Figure 2-1. It is a complex diterpenoid 
molecule which has an 8-member taxane ring, a 4-member oxetane ring and an ester side 
chain at C-13. It is a white to off-white crystalline powder with the empirical formula 
C47H51NO14 and a molecular weight of 853.9. It is highly lipophilic, insoluble in water, 











Figure 2-1 Molecular structure of paclitaxel 
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Paclitaxel can promote the formation of microtubules from tubulin dimmers. It can 
prevent depolymerization of microtubules and stabilize the microtubules, which involve 
cellular nutrition ingestion, movement, shape control, sensory transduction and spindle 
formation. The stability of microtubules can inhibit the mitosis of tumor cells and thus 
lead them death (Donehower et al. 1987; Rowinsky et al. 1990; Lopes et al. 1993). 
However, the usage of paclitaxel is limited by its availability. For example, in order to get 
2 g paclitaxel for treatment of one patient, four trees of one hundred years have to be 
sacrificed. The yew tree sources are limited and this kind of method is not accepted from 
the environmental view. Moreover, full synthesis of paclitaxel is very expensive as two 
hundred steps have to be done. Now the source of paclitaxel is from the semi-synthesis 
method by extracting precursors for the synthesis of paclitaxel from needles and twigs of 
English yew trees or Chinese red bean yew trees. And the tree does not need to be 
sacrificed after extracting for semi-synthesis method. Moreover, the clinical direct use of 
paclitaxel is also limited by its high hydrophobicity. The bulky taxane skeleton and the 
peripheral aromatic rings combined with a propensity to self-aggregate makes paclitaxel 
poorly soluble in water. The solubility in water has been reported as 0.7, 6 and 30 µg/ml 
(Swindell et al., 1991; Mathew et al. 1992).  
 
The available dosage form in clinical administration is Taxol® from Bristol Mayer Squibb, 
which is formulated in an adjuvant called Cremophor EL (polyethoxylated caster oil). 
Intensive research has shown that Cremophor EL is responsible for many serious side 
effects of taxol including hypersensitivity reactions, nephrotoxicity, cardio toxicity and 
neurotoxicity (Weiss et al., 1990; Kongshaug et al., 1991; Rowinsky et al., 1992; 
Fjallskog et al., 1993; Webster et al., 1993; Kohler & Goldspiel, 1994).  
 16
2.2.3.2 Docetaxel 
Docetaxel is a semisynthetic analog of paclitaxel, but is more effective as an inhibitor of 
microtubule depolymerization owing to its ability to alter tubulin processing within the 
cells (Gueritte-Voegelein F et al., 1991).  It is an esterified product of 10-deacetyl baccatin 
III, which is extracted from the renewable and readily available European yew tree. The 
molecular structure of docetaxel is shown in Figure 2-2 and it can be found that the 
chemical structure of docetaxel differs from paclitaxel at two positions. Docetaxel has a 
hydroxyl functional group on carbon 10 whereas paclitaxel has an acetate ester and a tert-
butyl substitution on the phenylpropionate side chain (Clarke & Rivory, 1999). Though 
the change of the carbon 10 functional group increases its water solubility, docetaxel is 









Figure 2-2 Molecular structure of docetaxel 
 
Together with paclitaxel, they belong to a class of chemotherapeutic agents known as the 
taxanes, which stabilize microtubules by promoting assembly while inhibiting 
disassembly. Although they share the same mode of action, docetaxel is about twice as 
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potent as paclitaxel as an inhibitor of spindle depolymerization (Cunha et al., 2001). 
Docetaxel is considered a better cytotoxic antimicrotubule agent than doxorubicin, 
paclitaxel and fluorouracil because of its higher affinity and potency in inhibiting cell 
replication and tumor cell growth (Lamb & Wisemam, 1998; Lyseng-Williamson & 
Fenton, 2005). Besides, it has also been found to have higher cellular uptake and achieves 
a longer retention time in vitro than paclitaxel, thus allowing docetaxel treatment to be 
effective with a smaller dose, leading to fewer and less severe adverse effects (Eisenhauer 
& Vermorken, 1998). Furthermore, docetaxel may be active against some tumors that are 
resistant to paclitaxel (Valero et al., 1998).  Besides its main use in the treatment of 
locally advanced or metastatic breast and non small-cell lung cancer after the failure of 
anthracycline-based chemotherapy, clinical data has also proven its cytotoxic activity 
against a wide spectrum of other cancers such as colorectal, ovarian, prostate, liver, renal, 
gastric, head and neck cancers as well as melanoma (Lyseng-Williamson & Fenton, 2005). 
 
The clinical dosage form of docetaxel is Taxotere®, which is formulated in the adjuvant 
consisting of nonionic surfactant Tween 80® (polysorbate 80) and ethanol, which has been 
proved to arouse side effects such as neurotoxicity, fluid retention and musculoskeletal 
toxicity (Verweij, 1994; Lavelle et al., 1995; van Zuylen et al., 2001). To avoid using the 
toxic adjuvant and decrease infusion period, more and more alternative formulations are 
developed to get the best clinical effects of paclitaxel which include prodrugs, liposomes, 
micelles, micro/nanoparticles, cyclodextrins complexes, submicron lipid emulsion etc 
(Lundberg, 1997; Lundberg et al., 2003). Among those formulations, nanoparticles of 
biodegradable polymers as a drug delivery system have attracted continuous interest in 
past years, which provide a way for drug formulation devoid of harmful adjuvant, realize 
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controlled drug release and thus achieve better therapeutic efficacy than the 
chemotherapeutic agents (Soppimath et al., 2001; Feng & Chien, 2003; Feng, 2006).  
 
2.3 Nanoparticles 
Polymeric nanoparticles can be used as therapeutics containing small-molecule drugs, 
peptides, proteins, as well as nucleic acids. Recently, biodegradable nanoparticles have 
attracted great interest due to their advantages over conventional therapeutic strategies. 
Types of polymeric nanoparticle include polymer micelles, liposomes and polymer-based 
nanoparticles. Compared to conventional therapeutic strategies, they could improve the 
solubility of poorly soluble drugs and increase drug half-life and specificity to the target 
sites (Gref et al., 1995; Anderson & Shive, 1997; Mundargi et al., 2008). Furthermore, 
most nanoparticles preferentially accumulate within tumors via the enhanced permeability 
and retention (EPR) effect (Shenoy et al., 2005). Thus, polymeric nanoparticles allow for 
enhancing the intracellular drug concentration in cancer cells while avoiding toxicity in 
normal cells, resulting in potent therapeutic effects. 
 
The material properties of each nanoparticle system have been developed to enhance 
delivery to the tumor. For example, hydrophilic surfaces can be used to provide the 
nanoparticles with stealth properties for longer circulation times and positively charged 
surfaces can enhance endocytosis. There are a variety of nanoparticle systems being 
developed for cancer therapeutics (Byrne et al., 2008). Nanoparticles can be tailor-made to 
achieve both controlled drug release and disease-specific localization by altering the 
polymer characteristics and surface chemistry (Kreuter, 1994; Moghimi et al., 2001; 
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Panyam & Labhasetwar, 2003). As Liggins et al. (Liggins et al., 2000) demonstrated 
microparticles with particles size less than 8 µm may be cleared 20 from the peritoneum 
into the lymph nodes and the paclitaxel-loaded PLGA microspheres with size around 30-
120 µm and 30% drug loading can prevent the growth of tumors in the peritoneal cavity. 
The particles can release the drug more than 30 days (Shieh et al., 1997). Paclitaxel-
loaded p(DAPG-EOP) microspheres can inhibit significantly the tumor growth in nude 
Balb/c mice. The tumor volume for A549 and H1299 nodules were doubled after 60 and 
35 days respectively after treated with microspheres which was much longer time than 10 
and 11 days respectively after treated with conventional paclitaxel by intratumoral 
administration (Harper et al., 1999).  
 
Comparing with microspheres/particles, nanoparticles with particles size less than 1 µm 
diameter have smaller size and thus higher surface area. Polymeric nanoparticles 
formulations of anticancer drugs demonstrate a promising approach to reduce the uptake 
of drug to reticuloendothelial system after intravenous injection, provide a controlled 
release of drugs, target the drugs to tumors, improve body distribution of drugs, reduce 
side effects from drug or adjuvants and thus lead to high therapeutic efficacy (Kim et al., 
2003). In oral delivery vehicles, the major interest is in lymphatic uptake of the vehicles. 
The size and surface charge of particles are crucial for the uptake. The optimum size for 
the uptake ranges from less than 1 µm to less than 5 µm (Torche et al., 2000). 
Nanoparticles have been found to bind the apical membrane of the M cells and then 
rapidly internalize and shuttle to the lymphocytes (Florence & Hussain, 2001). 
Nanoparticles are better suited for i.v. delivery as the smallest capillaries in the body are 
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5-6 µm in diameter and the size of particles must be significantly less than 5 µm to avoid 
forming an embolism in the bloodstream (Hans & Lowman, 2002).  
 
2.3.1 Nanotechnology 
Nanotechnology is a multidisciplinary field and can be defined as the science and 
engineering involved in the design, synthesis, characterization and application of materials 
and devices whose smallest functional organization in at least one dimension is on the 
nanometer scale (Emerich & Thanos, 2003). Nanotechnology covers a vast and diverse 
array of devices derived from engineering, physics, chemistry, and biology. Since the 
discovery of carbon nanotubes and their unusual properties in 1991, the hope for the 
potential of nanotechnology to better diagnose and treat cancer has blossomed. 
Applications of nanotechnologies in medicine are especially promising (Roco, 2003). 
Nanotechnology opens the door to a new generation of cancer diagnosis and therapy. It 
enables researchers to create nano-sized particles containing not only diagnostic agents to 
image cancer cells, but also anticancer drugs to kill cancer cells, respectively, at the early 
stage of cancer. Unlike previous revolutions in the fighting against cancers that raised 
hopes, nanotechnology “is not just one more tool, it’s an entire field and will pervade 
everything in medicine,” said Mauro Ferrari, an expert in cancer nanotechnology at Ohio 
State University, US. Especially, in recent ten years, nanotechnology has been developed 
and widely investigated in cancer chemotherapy and it may promote new concept 
chemotherapy, cancer chemotherapy at home. Nanotechnology has pushed personalized 
medicine under way for years, which can be realized by nanoparticles containing 
antineoplastic agents, targeting compounds and diagnosis agents (Feng & Chien, 2003). 
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2.3.2 New-concept chemotherapy 
Chemotherapy is a complicated procedure in which many factors are involved in 
determining its success or failure. There has been no substantial progress in the past 50 
years in fighting cancer. Cancer nanotechnology will fundamentally change the way we 
diagnose, treat and prevent cancer. A new concept of chemotherapy may include sustained, 
controlled and targeted chemotherapy. Meanwhile, personalized chemotherapy is to be 
developed including chemotherapy across various physiological drug barriers such as the 
gastrointestinal (GI) barrier for oral chemotherapy and the blood-brain barrier (BBB) for 
the treatment of brain tumors, and eventually chemotherapy at home (Feng, 2004; Feng, 
2006). In the development of a new concept in chemotherapy, an ingenious approach in 
chemotherapeutic engineering, by modifying the delivery technique of drugs more 
effectively into the body system for treatment had been developed. This maybe a more 
feasible approach as compared to the researching and discovering new anti-cancer drugs 
in order to evade the problems faced by the current chemotherapy treatment as mentioned 
in the previous section.  
 
The success in bioavailability will eventually lead to oral chemotherapy, a new concept of 
chemotherapy, “chemotherapy at home”, which has more advantages over the 
conventional chemotherapy method by injection or infusion. In the future, chemotherapy 
engineering may be able to develop highly effective as well as minimal side effects 
therapies with targeting functions for all kind of cancers. Also, the administration of drug 
may be extended not only intravenously and orally but also through skin patch, nasal 
forms (Fernandez-Urrusuno et al., 1999; Feng, 2004). Moreover, personalized therapy 
will also be possible which is customized to fulfill individuals’ requirements.  
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2.3.3 Nanoparticle fabrication 
Nanoparticles can be fabricated by polymerization or dispersion of the performed 
polymers which includes solvent extraction/evaporation method, salting-out method, 
dialysis method, supercritical fluid spray technique and nanoprecipitation method. Solvent 
extraction/evaporation is used in current research due to the acceptable drug loading 
efficiency, ease of processing and good reproducibility.  
 
2.3.3.1 Solvent extraction/evaporation technique 
Solvent extraction/evaporation technique is the most widely used technique for 
nanoparticles fabrication. In this technique, the selected polymer is firstly dissolved in an 
organic solvent such as dichloromethane, chloroform and ethyl acetate. The hydrophobic 
anticancer drug is then dissolved in the polymer solution. The formed solution is dispersed 
in an aqueous phase with/without surfactant/stabilizer such as PVA, gelatin, poloxamer 
188, DPPC, TPGS, etc. The mixture is emulsified by either high-speed homogenization or 
high voltage sonicator leading to the formation of an oil-in-water emulsion. After a stable 
emulsion is formed, the organic solvent is evaporated under increased temperature, 
reduced pressure or continuously stirring at room temperature. After that, the solvent-free 
emulsion is centrifuged, re-suspended, and then lyophilized to get the resulted particles 
(Mu & Feng, 2003; Mu et al., 2004).  
 
The pharmaceutical characteristics of the nanoparticles can be influenced by many factors 
in the process of fabrication, such as the matrix concentration in solvent, the ratio of 
organic to aqueous phase, the type and concentration of emulsifiers, the drug loading ratio, 
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strength of mixing energy in emulsifying and evaporation, and post treatment of 
nanoparticles including centrifugation, washing, lyophilization, sterilization, pH condition 
as well as temperature (Mu & Feng, 2003).  
 
2.3.3.2 Nanoprecipitation method 
Nanoprecipitation is a nanoparticle synthesis process involving solvent displacement, 
followed by interfacial deposition of pre-formed polymer. This technique was developed 
by Fessi et al. (Fessi et al.,1989). The oily phase commonly used is water-soluble organic 
solvents such as acetone, acetonitrile and dimethylformamide. Pre-formed polymer and 
drug are dissolved in the organic phase. When the organic phase is mixed droplet by 
droplet with the aqueous phase under gentle magnetic stirring, an emulsification is formed 
spontaneously. The solvent is evaporated overnight with gently stirring. The particles are 
collected by filtration to remove the aggregation, centrifugation, and lyophilization. 
 
The poly(D, L-lactide) (PLA) nanoparticle prepared by Fessi et al. (Fessi et al., 1989) was 
about 250nm with nearly 100% encapsulation efficiency. Dong & Feng (Dong & Feng, 
2004) fabricated paclitaxel-loaded nanoparticles of PLA-MPEG copolymers by 
nanoprecipitation method with/without stabilizer, poloxamer 188. The particles size was 
less than 100 nm and the particles can release the drug in a controlled manner in a period 
of around 15 days. Nanoprecipitation method has distinct advantages such as minimizing 
the usage of potentially toxic components including chlorinated solvents and surfactant, 
and producing smaller particles size (sub-200 nm) with narrow size without external 
energy (Chorny et al., 2002; Dong & Feng, 2004). The advantage of nanoprecipitation is 
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the instantaneous formation of nanoparticles and self-assembly process without high 
external energy source. However, nanoprecipitation is not recommended for encapsulation 
of highly hydrophilic drugs due to the low affinity of the drugs with the polymer which 
may result in low encapsulation efficiency (Barichello et al., 1999). 
 
2.3.3.3 Dialysis method 
Dialysis is another self-assembling method of nanoparticles fabrication. Like 
nanoprecipitation technique, nanoparticles can be fabricated with/without 
surfactant/additive/stabilizer. The mechanism of dialysis in nanoparticles fabrication is not 
well-understood (Nah et al., 2000), but it is believed to be akin to interfacial turbulence 
phenomena described by Fessi et al. (Fessi et al. 1989). To synthesize nanoparticles using 
dialysis method, drug and preformed polymer are dissolved in a water-miscible organic 
solvent. The solution is then transferred into a cellulose membrane bag which is then 
immersed in a container filled with water for one or two days. The water is exchanged at 
certain interval to maintain the osmotic pressure which removes the solvent and unloaded 
drug out from the membrane bag. The nanoparticle solution was then centrifuged to 
eliminate the unloaded drug. After that, the nanoparticles are resuspended into water and 
lyophilized overnight.  
 
In dialysis, the molecular weight cut-off (MWCO) of the membrane is one of the 
additional controlling factors which may influence the suitability of dialysis for some 
polymers (Vangeyte et al., 2004). Also, the porosity of the membrane controls the rate at 
which the organic phase is dialyzed, thus affecting the size of nanoparticles. The dialysis 
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performed by Vengeyte et al. yielded poly(ethylene oxide)-b-poly(ε-caprolactone) (PEO-
b-PCL) nanoparticles of about 540nm using tetrahydrofuran (THF) as the organic solvent 
and cellulose membrane with MWCO of 8,000 (Vengeyte et al., 2004). Xie & Wang (Xie 
& Wang, 2005) fabricated PLGA and PLA nanoparticles with size around 300 nm and 
3.5% paclitaxel loading. The drug encapsulation efficiency in nanoparticles by dialysis 
technique is lower compared with solvent extraction/solvent method, up to 100%. When 
the theoretical drug loading was excess of 10%, crystalline form of paclitaxel can be found 
from XRD, DSC and FESEM results. Zhang & Feng (Zhang & Feng, 2006b) synthesized 
PLA-Tween 80 nanoparticles, with size around 150nm and 65% encapsulation efficiency, 
using membrane with MWCO of 3,500. The main limitations of dialysis are that it is time-
consuming and large volume of tank is required. Therefore, large scale operation may not 
be feasible.  
 
2.3.3.4 Salting-out method 
Salting-out technique is based on the water-miscible solvent from aqueous solutions via a 
salting-out effect, which applies the physical property of solubility to fabricate 
nanoparticles. In the case of nanoparticles fabrication, the salting-out agent, such as 
sodium chloride and magnesium chloride, dissolved in the aqueous phase interacts with 
water stronger than the water-miscible organic solvent, resulting in phase separation due 
to decrease of ‘space’ available for the organic solvent. Together with a vigorous 
mechanical stirring and fast addition of pure water, the organic solvent will then diffuse 
into the aqueous medium and form an emulsion in the aqueous phase, with the drug being 
entrapped in nanoparticles, when the polymer deposits onto the oil/water interface to 
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reduce the high interfacial energy (Quintanar-Guerrero et al., 1998). Stabilizer or 
surfactant is normally added to further stabilize the particle suspension. Successful 
stabilizers include PVA, polyvinyl pyrolidone and hydroxyethyl cellulose (Allemann et al., 
1992; Leroux et al., 1994). The nanoparticles can then be collected by cross-flow filtration 
or centrifugation to remove the organic solvent and other salting-out agents. Acetone is 
widely used as the water-miscible solvent because of its solubilizing property and ability 
of separation from aqueous solutions by salting-out with electrolytes. Nguyen et al. 
(Nguyen et al., 2003) prepared PLA-MPEG copolymers nanoparticles with particle size 
around 300 nm. Sub-200 nm PLGA nanoparticles can be obtained by optimization of the 
salting-out process parameters, adding lyoprotectants such as saccharides to protect 
particles from aggregation and filtration through 0.22 µm membrane filters (Konan et al., 
2002). This method is simple, easy to be scaled up and relatively cheaper compared to 
other techniques. Besides that, this technique is able to entrap high amount of drugs in 
nanoparticles. However, the method is limited to encapsulation of hydrophobic drugs. 
 
2.3.4 Nanoparticle properties 
Important physicochemical properties would determine the in vitro and in vivo 
performance of nanoparticles. These properties of nanoparticles include particle size and 
size distribution, surface morphology, surface chemistry, surface charge, surface 
adhesion/erosion, drug diffusivity, drug encapsulation efficiency, drug stability, drug 
release kinetics, etc. The controlling parameters in achieving an optimal design include the 
polymer type as well as the molecular weight, the copolymer blend ratio, the type of 
organic solvent used, the emulsifier/stabilizer added, the oil-to-water phase ratio, the 
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mechanical strength of mixing, temperature, pH, etc. Among these, the polymer type, its 
molecular weight and the copolymer blend ratio are major factors in determining the 
degradation rate of the NPs and thus the in vitro and in vivo release of the encapsulated 
drug.  
 
Emulsifier also plays an important role in stabilizing the colloidal suspension during NP 
fabrication. Poly(vinyl alcohol) (PVA) has been preferentially chosen as 
emulsifier/surfactant/stabilizer in nanoparticles fabrication due to its excellent stabilizing 
ability to avoid particles aggregation during post-preparative steps (e.g. freeze-drying and 
purifying), high yield of dry particles powder and easy to be redispersed in solution after 
lyophilized (Quintanar- Guerrero et al., 1998). It has also been found that PVA may be 
absorbed or tightly associated with the surface layer and thus can not be completely 
removed from the surface of nanoparticles from GPC, SSIMS and XPS results 
(Shakesheff et al., 1997; Lee et al., 1999; Scholes et al., 1999). Therefore, PVA can not 
being accepted as surfactant for i.v. administration although its safety has been revised 
(Yamaoka et al., 1995).  
 
DPPC and TPGS were also found to be excellent emulsifiers in fabricating paclitaxel-
loaded nanoparticles (Mu & Feng, 2003; Mu et al., 2004). Phospholipids with short and 
saturated chains showed higher efficiency in emulsion of polymeric micro/nanospheres of 
better physical/chemical properties (Feng & Huang, 2001). There is not significant 
difference in morphology between TPGS and PVA emulsified PLGA nanoparticles but 
TPGS can improve the encapsulation efficiency of paclitaxel loaded in nanoparticles up to 
100% compared with PVA emulsified nanoparticles, 59%. Moreover, the amount of 
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TPGS needed in the fabrication process was only 0.015% (w/w), which was far less than 
1% for PVA needed in similar process (Feng et al., 2002; Mu et al., 2002; Mu et al., 
2003).  
 
2.4 Vitamin E TPGS 
2.4.1 Introduction to Vitamin E TPGS 
D-α-Tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS or simply, TPGS) 
was developed in the 1950s as a non-ionic water soluble derivative of natural vitamin E 
(Sokol et al., 1993; Chang et al., 1996). It is a PEGylated vitamin E, formed by 
esterification of d-α-Tocopheryl acid succinate with polyethylene glycol 1000. The 








Figure 2-3 Chemical structure of TPGS 
 
The amphiphilic structure of TPGS is composed of lipophilic alkyl tail and hydrophilic 
polar head, and the molecular weight of TPGS is approximately 1542 Da. HLB 
(hydrophile/lipophile balance) of TPGS is ~ 13. It is stable in air and reacts with alkali. 
Thermal degradation temperature is 199 °C and melt temperature is 38-41 °C. TPGS has 
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also very low critical micelle concentration (CMC), about 0.02 wt%. It forms micelles 
above the CMC and improve solubility of lipophilic compounds. Previous reports 
suggested that co-administration of TPGS enhanced oral absorption of cyclosporin A due 
to improved solubilization by micelle formation (Sokol et al., 1993; Boudreaux et al., 
1993).  
 
In 2005, TPGS was approved as a pharmaceutical excipient for oral drug formulations in 
Japan by the Japanese government’s Ministry of Health, Labour and Welfare 
(http://www.inpharmatechnologist.com 2005). National cancer institute indicates that the 
safety oral dosage of TPGS is larger than 1 g/kg/day as detected 
(http://www.eastman.com). The acute oral LD50 of the adult rats is greater than 7 g/kg for 
TPGS and its moieties such as polyethylene glycol 1000 and d-α-tocopheryl succinate 
(Katz et al., 1984). The bulky structure and large surface areas make TPGS an effective 
emulsifier and solubilizer (Wacher et al., 2002). It has been used as emulsifier, solubilizer, 
bioavailability enhancer of vitamin E and some hydrophobic drugs and colloidal drug 
delivery vehicles. TPGS is an effective emulsifier and coating agent. There are two stages 
in which TPGS can be involved in enhancing the emulsification. It can either be coated on 
the surface of the nanoparticles by adding TPGS during emulsification or be 
copolymerized with other polymers to form pre-formed copolymers before nanoparticles 
fabrication. In both ways, TPGS helps to improve drug encapsulation efficiency up to 




2.4.2 TPGS as a bioavailability enhancer 
To enhance the bioavailability of water insoluble pharmaceutical actives, non-ionic 
surface-active agents are commonly used in oral formulations, which include TPGS. As a 
non-ionic surfactant, TPGS can offer several advantages such as it provides better 
bioavailability and it is less toxic to biological membranes. As Traber et al. (Traber et al., 
1986; Traber et al., 1988; Traber et al., 1994) demonstrated, TPGS provided better 
bioavailability than the emulsified vitamin E form of tocopheryl acetate (emulsified with 
medium-chain triglycerides and polysorbate 80). It may be explained by TPGS forms 
micelles and can cross from the intestinal lumen through the unstirred water layer to the 
enterocytes and thus enhances α-tocopheryl absorption. Moreover, human cells 
experiment such as skin fibroblasts and Caco-2 cells have already demonstrated that 
TPGS can enhance tocopheryl content in the cells (Traber et al., 1988). Furthermore, 
TPGS has been shown to influence drug pharmacokinetics (Miller et al., 1999). 
 
When forming nanoparticles containing hydrophobic drugs, the polar functional group of 
TPGS is exposed to the aqueous phase while the large hydrophobic tail interacts with 
water-insoluble drug in the core, thus stabilizing the unstable water/oil interface. At the 
same time, TPGS can minimize the potential binding of lipophilic drug such as paclitaxel 
to blood components, lipids or cholesterols. Hence, the retention time of the free drug in 
the body is increased in systemic circulation. As a result, the volume of distribution 
required is relatively small while bioavailability is promoted. Research from Varma & 
Panchagnula (Varma & Panchagnula, 2005) revealed that the bioavailability of paclitaxel 
administered with TPGS was 6.3 times higher than administration of paclitaxel only.   
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2.4.3 TPGS as drug absorption enhancer 
TPGS has been described as an effective oral absorption enhancer for improving the 
bioavailability of poorly absorbed drugs. It could be absorbed intact readily in the 
gastrointestinal tracts, and was found to be one of the most effective P-gp inhibitors 
among the surfactants (Yu et al., 1999). P-gp is primarily expressed on the luminal surface 
of epithelial cells from several tissues such as intestine, liver, kidney, and the endothelial 
cells (Thiebaut et al., 1987). TPGS can improve the permeability of a drug across cell 
membranes by inhibiting P-glycoprotein (P-gp), and thus enhance absorption of a drug 
through the intestinal wall and into the bloodstream. TPGS could enhance the cytotoxicity 
of anticancer drugs such as doxorubicin and paclitaxel (Dintaman et al., 1999). Besides 
that, research has found that TPGS increases the cell uptake of PLA-TPGS nanoparticles 
in human colon cancer cells HT-29 up to about 2 times more than PVA-emulsified PLGA 
nanoparticles (Zhang & Feng, 2006c). The reason is that TPGS has the potential to inhibit 
efflux pump of P-glycoprotein (P-gp) found primarily in intestinal lining, kidney and liver 
(Zhang & Feng, 2006d) so as to promote absorption of anticancer agents. Results from 
Feng et al. (Feng et al., 2009) showed that the bioavailability of docetaxel formulated in 
TPGS emulsified PLA-TPGS nanoparticles was more than 24 times higher than 
administration of Taxotere® only. 
 
2.4.4 Other applications 
TPGS is PEG 1000-conjugates to α-tocopheryl succinate (α-TOS), which is a succinyl 
derivative of Vitamin E. The antineoplastic effects of α-TOS have been shown in 
numerous studies both in vitro and in vivo (Stapelberg et al., 2004; Neuzil et al., 2004). α-
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TOS has been demonstrated to induce apoptosis in multiple carcinoma cell lines and to 
inhibit the growth of several tumor types in animal models (Crispen et al., 2007; Freitas et 
al., 2009). For example, it has been found that α-TOS exerts anticancer properties against 
leukemias, melanomas, breast, colorectal, malignant brain, lung and prostate cancers 
(Malafa et al., 2000; Swettenham et al., 2005). α-TOS was found to inhibit tumor growth 
in animals by alone or in combination with other anticancer agents whereas being non-
toxic to normal cells such as haematopoietic cells, fibroblasts, endothelial cells and 
smooth muscle cells (Weber et al., 2002; Barnett et al., 2002). α-TOS can involve the 
generation of reactive oxygen species (ROS) which can damage DNA, proteins and fatty 
acids in cells and thus lead to cell apoptosis (Ottino & Duncan, 1997; Wang et al., 2005). 
As α-TOS has poor water solubility, some other Vitamin E analogues were found to be 
much effective or inactive against cancers as Birringer et al. (Birringer et al., 2003) 
demonstrated. The anticancer property of TPGS was concerned by Youk et al. (Youk et 
al., 2005) who found that TPGS can more effectively inhibit the growth of human lung 
carcinoma cells from in vitro cell culture and implanted in nude mice than that of α-TOS.  
 
2.5 Targeted therapy 
2.5.1 Introduction to targeted therapy  
Although problems with conventional chemotherapy in terms of its formulation, 
pharmacokinetics and drug resistance may be solved with the help of nanotechnology, 
toxicity issues still remain, which is the main obstacle to the development of effective 
chemotherapy. Hence, there is a clear need to explore effective targeting methods to 
improve the delivery of drugs to tumors.  
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Targeted therapy is defined as a type of treatment that uses drugs or other substances to 
identify and attack specific cancer cells (Allen, 2002). Targeted therapy may be more 
effective and have fewer side effects than other types of cancer treatments. Current cancer 
therapy usually involves intrusive processes to allow chemotherapy to shrink any cancer 
present, surgery to remove tumor if possible. For the majority of patients with advanced 
stage of cancer the treatment is limited to chemotherapy or radiation. The purpose of 
chemotherapy and radiation is to kill the cancer cells as these cells are more susceptible to 
the actions of these drugs and therapies as they grow at a much faster rate than healthy 
cells. The effectiveness of the treatment is directly related to the treatment’s ability to 
target and to kill the cancer cells while affecting as few healthy cells as possible.  
Moreover, the degree of change in the patient’s quality of life and eventual life expectancy 
is directly related to the targeting ability of the treatment (Fitzgerald & Pastan, 1989; 
Allen, 2002).  
 
Though there have been several decades of research and development, targeted delivery 
has not yet fulfilled the initial promise in the treatment of cancer. The targeted delivery of 
anticancer drugs to solid tumors is a complicated issue because of the impediments to drug 
delivery (Poste & Kirsh, 1983; Brigger et al., 2002). The major impediments to drug 
delivery arise from tumor heterogeneity. Cancer cells typically occupy less than half of the 
total tumor volume, among which approximately 1~10% is contributed by tumor 
vasculature, and the rest is occupied by a collagen-rich interstitium.  The heterogeneous 
distribution of blood vessels, antigen and receptor expression in tumors is also a problem 
in affinity-targeted delivery of drugs to solid tumors (Jain, 1994; Jain, 1999). 
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The development of a wide spectrum of nanoscale technologies has tremendous potential 
to make an important contribution in cancer prevention, diagnosis, imaging, and treatment 
(Balshaw et al., 2005; Nie et al., 2007). These technological innovations have the 
potential to turn molecular discoveries arising from genomics and proteomics into 
widespread benefit for patients. These devices include, but are not limited to, 
functionalized carbon nanotubes, nanomachines, magnifiers, self-assembling polymeric 
nanoconstructs, nanomembranes, and nano-sized silicon chips for drug, protein, nucleic 
acid, or peptide delivery and biosensors and laboratory diagnostics. In terms of 
biodegradable polymeric nanoparticles, targeting ability can be achieved by 
functionalizing the surface of drug-loaded nanoparticles with targeting ligands which can 
then recognize and bind to certain receptors overexpressing on the membrane of the 
cancer cells.  
 
Targeted cancer therapies interfere with cancer cell growth and division in different ways 
and at various points during the development, growth, and spread of cancer. Many of 
these therapies focus on proteins that are involved in the signaling process. Molecular 
targeted therapies target tumor antigens to alter the signaling either by monoclonal 
antibodies (mAb) or by small molecule drugs that interfere with these target proteins. By 
blocking the signals which tell cancer cells to grow and divide uncontrollably, the 
approaches can help to stop the growth and division of cancer cells. This new type of 
approaches has been termed as targeted therapy, the goal of which is to provide molecular 
levels-based agents that are more specific for cancer cells (Mothersill & Seymour, 2006). 
Targeted therapies are also often useful in combination with cytotoxic chemotherapy or 
radiation to produce additive or synergistic anticancer activity because their toxicity 
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profiles often do not overlap with traditional cytotoxic chemotherapy. Thus, targeted 
therapies represent a new and promising approach to cancer therapy leading to beneficial 
clinical effects. There are multiple types of targeted therapies available, including 
monoclonal antibodies, tyrosine kinases inhibitors, and antisense inhibitors of growth 
factor receptors. 
 
2.5.2 Passive and active targeting 
2.5.2.1 Passive targeting 
Targeted delivery can be achieved in two manners, namely, passively and actively. 
Passive targeting makes use of the tumor microenvironment which is characterized by a 
leaky tumor vasculature and a dysfunctional lymphatic drainage system. Most polymeric 
nanoparticles display the EPR effect, which is a consequence of the increased vasculature 
permeability and decreased lymphatic function of tumors. It occurs when nanoparticles 
extravasate out of the tumor microvasculature, leading to an accumulation of drugs in the 
tumor interstitium (Seymour, 1992). Thus passive targeting is achieved by incorporating 
the therapeutic agent into a macromolecule or nanoparticle that passively reaches the 
target organs through the EPR effect.  
 
Passive targeting also involves the use of other innate characteristics of the nanoparticles 
which can induce targeting to the tumor, such as surface charge. For example, cationic 
liposomes are found to exhibit a tendency to bind through electrostatic interactions to 
negatively charged phospholipid headgroups preferentially expressed on tumor endothelial 
cells (Thurston et al., 1998; Krasnici et al., 2003). Catheters can be alternatively used to 
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infuse nanoparticles to the target organ or tissues. For example, localized delivery of drug-
loaded nanoparticles to sites of vascular restenosis may be helpful provide sustained drug 
release at specific sites on the arterial wall (Maeda, 2001). 
 
For passive targeting to be successful, the nanoparticles with chemotherapeutic agents 
encapsulated have to circulate in the blood for extended time so that there will be multiple 
possibilities for the nanoparticles to pass by the target sites. Nanoparticles normally have 
short circulation half-lives due to natural defense mechanisms of the body to eliminate 
them after opsonization by the mononuclear phagocytic system (MPS) (Owens & Peppas, 
2006). Therefore, the particle surfaces need to be modified to be invisible to opsonization. 
A number of studies applied various surface modification approaches to classical 
nanocarriers to increase their circulation half-lives for effective passive targeting or 
sustained drug effect. These approaches include incorporation of linear dextrans, sialic 
acid-containing gangliosides, and lipid derivatives of hydrophilic polymers such as PEG 
to provide steric stabilization around the liposomes for protection from the MPS uptake 
(Allen & Chonn, 1987;Lee, 2004). For example, polyethylene glycol (PEG), a hydrophilic 
polymer is commonly used to lengthen the circulation time, as PEG has desirable 
attributes such as low degree of immunogenicity and antigenicity, chemical inertness of 
the polymer backbone, and availability of the terminal primary hydroxyl groups for 
derivatization (Rossi et al., 2007). 
 
Passive targeting results in high drug concentration in tumors and reduced drug toxicity to 
the normal tissues. However, the biggest limitation of passive targeting lies in its inability 
to deliver a sufficiently high level of drug concentration to the tumor site (Boghaert et al., 
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2006). Currently, this technology lacks tumor specificity and the ability to control the 
release of the entrapped agents. Therefore the focus has gradually shifted from passive 
targeting to the development of nanoparticle as drug delivery systems with active targeting 
functions. 
 
2.5.2.2 Active targeting 
In comparison with passive targeting exploiting the characteristic features of tumor 
biology that allow nanocarriers to accumulate in the tumor by the EPR effect, active 
targeting is achieved by delivering drug encapsulated nanoparticles to uniquely identified 
sites while having minimal side effects (Peer et al., 2007). There are still several 
limitations in passive targeting approaches although they form the basis of clinical therapy. 
Certain tumors do not exhibit the EPR effect and the permeability of vessels may not be 
the same through a single tumor (Jain, 1994). It is difficult to control the passive targeting 
process due to the inefficient diffusion of some drugs as well as the random nature of the 
approach. Thus multiple-drug resistance (MDR) might occur, which is a situation where 
chemotherapy treatments fail patients owing to the resistance of cancer cells to one or 
multiple different drugs (Shen et al., 1986; Pastan et al., 1987). MDR happens when 
transporter proteins that expel drugs from cells are overexpressed on the surface of cancer 
cells. This drug resistance at its worst, when the toxic side effects are still there in full 
force, will kill healthy cells in the body but have no harmful effects towards the cancer 




Active targeting attempts to take advantage of overexpressed tumor associated antigen or 
receptors to selectively target the drug to the tumor and is in general achieved through the 
administration of nanoparticles with cell-specific ligands conjugated on the surface of 
nanoparticles. These ligands can recognize and then bind to specific ligands that are 
uniquely expressed on cancer cells. In the case of local drug delivery, the cytotoxic drug 
encapsulated in the nanoparticles can be delivered directly to cancer cells while 
minimizing harmful toxicity to healthy cells adjacent to the target tissue (Ciardiello & 
Tortora, 2001; Byrne et al., 2008).  
 
2.5.3 Small molecule tyrosine kinases inhibitors 
Protein tyrosine kinases (PTKs) are enzymes that catalyze the phosphorylation of tyrosine 
residues and are especially important targets as they play an important role in the 
modulation of growth factor signaling and oncogenic transformation of cells (Blume-
Jensen & Hunter, 2001). There are two main classes of PTKs: receptor PTKs and non-
receptor PTKs. Human genome sequence analysis has identified about 518 human protein 
kinases, among which at least 90 tyrosine kinase genes have been identified (Manning et 
al., 2002). These enzymes are involved in cellular signaling pathways and regulate key 
cell functions such as proliferation, differentiation, anti-apoptotic signaling and neurite 
outgrowth. A significant number of tyrosine kinases are associated with cancers and they 
play a critical role in the regulation of fundamental cellular processes including cell 
development, differentiation, proliferation, survival, growth, apoptosis, cell shape, 
adhesion, migration, cell cycle control, T-cell and B-cell activation, angiogenesis, 
responses to extracellular stimuli, neurotransmitter signaling, platelet activation, 
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transcription, and glucose uptake (Arkin & Wells, 2004; Gschwind et al., 2004; Krause & 
Van, 2005). 
 
Receptor tyrosine kinases are multi-domain proteins. Several approaches to target PTKs 
have been developed and classification of such inhibitors based on the mode of action.  It 
has been found that activation of protein phosphorylation-related pathways in tumors can 
occur through overexpression if compared to normal cells (Bridges, 1996; Longati et al., 
2001). Therefore, the targeted therapeutics ascribes to therapeutic agents that are as close 
to be mono-specific as possible to avoid the harmful side effects, which sometimes arose 
with traditional cancer therapies. For this reason, small molecule inhibitors of protein 
kinases have emerged as essential for studying targeted therapy and these drugs are also 
called signal-transduction inhibitors (Smith et al., 2004). 
 
Among the tyrosine kinases, the epidermal growth factor receptor (EGFR) family is the 
most widely investigated. EGFR is the cell-surface receptor for members of the EGFR 
family of extracellular protein ligands (Mendelsohn & Baselga, 2000). The EGFR is a 
member of the ErbB family of receptors, a subfamily of four closely related receptor 
tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), HER3 (ErbB-3) and HER4 
(ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. EGFR 
exists on the cell surface and is activated by binding of its specific ligands, including 
epidermal growth factor and transforming growth factor α (TGFα) (Blobe et al., 2000). 
Overexpression of the EGFR has been associated with a poor prognosis in a variety of 
solid tumors and thus represents an attractive therapeutic target (Mendelsohn & Baselga, 
2000).   
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Gefitinib (Iressa®) and erlotinib (Tarceva®) are two small molecule drugs that have been 
developed as inhibitors of the EGFR tyrosine kinase (Haas-Kogan et al., 2005). Gefitinib 
is a selective EGFR (ErbB1) tyrosine kinase inhibitor and it has a 200-fold greater affinity 
for ErbB1 compared with that for ErbB2. Gefitinib can inhibit the growth of some ErbB2-
overexpressing tumor cells such as breast cancer (Moulder et al., 2001). The specific 
mechanism of its antitumor activity is not clear, but it is speculated that up-regulation of 
the cyclin-dependent kinase inhibitor p27 via EGFR kinase inhibition leads to inhibited 
cyclindependent kinase activity and arrest in the G1 cell cycle phase (Blackledge & 
Averbuch, 2004). Erlotinib is a small-molecule tyrosine kinase inhibitor directed against 
the epidermal growth factor receptor (EGFR) and it is the first oral tyrosine kinase 
inhibitor to demonstrate improved overall survival in the treatment of advanced and 
metastatic non-small cell lung cancer (NSCLC) (Shepherd et al., 2005). Erlotinib received 
approval from the US Food and Drug Administration (FDA) in November 2004 for the 
second-line treatment of locally advanced NSCLC after the failure of more than 1 or 2 
previous chemotherapeutic regimens (Ranson, 2004). In an early clinical placebo-
controlled trail, patients randomized to erlotinib with advanced stage III or IV NSCLC and 
who had progressive disease after standard chemotherapies showed improved symptoms 
and increased survival, in which response rate was found to be 12% (Perez-Soler, 2004). 
In preclinical studies, erlotinib has substantial antitumor activity against various human 
tumor xenografts alone and in combination with chemotherapeutic drugs. It has been 
proved that erlotinib was well tolerated, with encouraging antitumor activity in patients 




2.5.4 Monoclonal antibody 
Monoclonal antibodies (mAbs) were first described by Kohler & Milstein in 1975 (Kohler 
& Milstein, 1975), who shared the Nobel Prize in Physiology or Medicine in 1984 for the 
discovery. Monoclonal antibodies target specific molecules and are used as passive 
immunotherapy to treat various diseases, including certain types of cancer. These mAbs 
selectively target tumor tissues and have been safely administered in cancer patients 
(Treon et al., 2001; Dillman, 2001). It was in the 1980s that the development of blocking 
mAbs to EGFR as a cancer therapy was proposed by Mendelsohm (Mendelsohn, 1997) for 
the first time. After that, more and more antibodies have become valuable therapeutic 
agents for targeting of extracellular proteins in various diseases, including cancer, 
autoimmunity and cardiovascular disorders (Rockberg et al., 2009). 
 
Development of mAb of human origin has proven to be a hard task. The first generation of 
humanized mAb was simply chimeric antibodies, in which the variable regions of murine 
mAb were linked to the constant region of a human IgG (Morrison et al., 1984). As 
expected, these humanized molecules should lack the immunogenicity of a murine mAb 
and interact more efficiently with the human immune system (Lobuglio et al., 1989). The 
second generation of humanized mAb was the reshaped antibodies, in which the antigen-
binding loops of the murine mAb were built into a human IgG (Jones & Ada., 1986). The 
main problem was related to specificity. It is usually not enough to maintain the original 
binding specificity by combining the complementarity-determining regions (CDRs) from 
the murine mAb with the frame-work of a human IgG, since several specific residues in 
the original murine framework contribute to maintain the CDR conformations. Molecular 
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modeling techniques allowed this problem to be resolved, and thus reshaped antibodies 
have successfully been produced and used for clinical purposes (Hale et al., 1988). 
 
The differences between mAbs and small molecule drugs lie in several pharmacological 
properties. Antibodies are administrated intravenously and act only on receptors expressed 
on the cell surface or secreted (Iannello & Ahmad, 2005). Small molecule tyrosine kinases 
inhibitors are orally available small, membrane-permeable synthetic compounds that block 
or compete with adenosine triphosphate (ATP) binding, thus inhibiting the intracellular, 
downstream signaling cascade stimulated by a receptor or several receptors. The half-life 
of many tyrosine kinase inhibitors, such as gefitinib, is approximately 24-48 h, whereas 
the half-life of monoclonal antibodies such as bevacizumab is about 3-4 weeks (Ignoffo, 
2004). mAbs cannot cross the blood-brain barrier efficiently due to their large size, 
whereas current evidence suggests that small molecules drugs can successfully cross the 
blood-brain barrier (Imai & Takaoka, 2006). Small molecules are generally less specific 
than therapeutic monoclonal antibodies, therefore a higher risk of toxicity potentially 
come along with small molecule drugs (Baselga, 2002).  
 
2.6 HER2 targeted therapy 
As has been stated in previous section, the EGFR family is thought to play a primary role 
in the control of epithelial cell proliferation and mutations affecting EGFR expression or 
activities that could result in cancer. The human epidermal growth factor receptor 2 
(HER2) is a member of the EGFR family, which is a receptor tyrosine-specific protein 
kinase family consisting of four semihomologous receptors, EGFR (ErbB1), HER2/neu 
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(ErbB2), HER3 (ErbB3) and HER4 (ErbB4). These receptors can interact with several 
ligands and generate intracellular signals as homodimer or heterodimer pairs 
(Spivakkroizman et al., 1992). HER2 is a cell membrane surface-bound receptor tyrosine 
kinase and is normally involved in the signal transduction pathways leading to cell growth, 
survival, and differentiation in a complex manner (Neve et al., 2001). HER2 levels 
correlate strongly with the pathogenesis and prognosis of breast cancer. The level of 
HER2 in human cancer cells with gene amplification is much higher than that in normal 
adult tissues, potentially reducing the toxicity of HER2-targeting drugs. It is well known 
that HER2 is overexpressed in 25–30% of invasive breast cancers but in normal tissues its 
expression is at a much lower level (Olayioye, 2001). HER2 overexpression is found in 
both the primary tumor and metastatic sites, indicating that anti-HER2 therapy may be 
effective in all disease sites (Tanner et al., 2001). Thus, HER2 is of great interest as an 
important therapeutic target in breast cancer (Slamon et al., 1989; Nobs et al., 2006). 
 
2.6.1 Assessment of HER2 status 
The HER2 status of a tumor is the critical determinant of response to trastuzumab as it 
provides prognostic information. Thus, accurate assessment of HER2 expression levels is 
essential for identifying breast cancer patients who will benefit from trastuzumab (Bartlett 
et al., 2003; Nahta & Esteva, 2003). There are several methods to test the HER2 levels 
and Testing can be done at the same time as initial breast cancer surgery, or samples of 
cancer cells from previous biopsies or surgery may be used. Two most widely used 
methods of measuring HER2 levels in the clinical setting are immunohistochemistry (IHC) 
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and fluorescence in situ hybridization (FISH). Both methods have been approved by FDA 
for selecting patients for trastuzumab-based therapy (Ellis et al., 2005). 
 
2.6.1.1 IHC 
IHC is widely used as it entails staining paraffin-embedded tissue with a HER2-specific 
antibody (Press et al., 2002). When using commercially available kits such as HercepTest 
(Dako, Carpinteria, CA) and Pathway HER2 (Ventana, Tucson, AZ), staining is graded 
semiquantitatively on a scale from 0 (no detectable HER2) to 3+ (high HER2 expression) 
on the basis of comparison with cell lines of known HER2 receptor density. Tumors with 
a staining score of 3+ are the most responsive to trastuzumab (Esteva et al., 2002). The 
disadvantages of IHC include the subjective interpretation and semiquantitative nature of 
results. Currently available IHC kits provide control slides against which samples are 
compared. Such standardization is essential to assuring accurate assessment of HER2 
status (Leonard et al., 2002). 
 
2.6.1.2 FISH 
FISH detects HER2 gene amplification and is more specific and sensitive than IHC 
(Persons et al., 2000). Importantly, FISH offers quantitative results, possibly eliminating 
subjectivity and variability among different laboratories. Furthermore, FISH predicts 
prognosis and response to trastuzumab more accurately than IHC does, as the subset of 
patients whose tumors overexpress HER2 in the absence of gene amplification are less 
likely to respond to trastuzumab-based therapy (Mass et al., 2001). In general, a 
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concordance rate of approximately 80% can be achieved by IHC and FISH (Jacobs et al., 
1999; Harris et al., 2001; Fornier et al., 2002). 
 
2.6.2 Trastuzumab (Herceptin®) 
Trastuzumab (Herceptin®) is a humanized monoclonal antibody that can specifically bind 
to the membrane region of HER2/neu with a high affinity and inhibit signal transduction 
as well as cell proliferation, which offers an excellent strategy for drug targeting due to the 
easy accessibility of HER2 (Carter et al., 1992; Vogel et al., 2001; Hudis, 2007). 
Trastuzumab was the first HER2-targeted therapy approved by the United States Food and 
Drug Administration (FDA) for the treatment of metastatic breast cancer (MBC), either in 
the first-line setting in combination with paclitaxel, or as monotherapy for patients who 
had received at least one prior chemotherapy regimen (Vogel et al., 2002; Romond et al., 
2005). 
 
2.6.2.1 Mechanisms of action of trastuzumab 
Trastuzumab consists of two antigen-specific sites binding to the HER2 receptor, which 
prevent the activation of its intracellular tyrosine kinase (Albanell et al., 1996). The 
mechanism of action of trastuzumab has not been fully characterized and appears to be 
complex. Trastuzumab exerts its antitumor therapeutic effects against tumor cells with 
HER2 overexpressed by several possible mechanisms. 
 
Herceptin reduces signaling from pathways that are activated by HER2, and thus promotes 
cell cycle arrest and apoptosis. These pathways include the PI3 kinase (PI3K) and MAP 
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kinase (MAPK) cascades. Research shows that HER2 remain the same level after 
trastuzumab-based treatment, therefore it is still unclear whether trastuzumab down-
regulates HER2 (Nahta et al., 2004).Trastuzumab therapy also increases membrane 
localization and activity of PTEN. Nagata et al. (Nagata et al., 2006) demonstrated that 
the interaction between HER2 and the Src tyrosine kinase is disrupted in response to 
trastuzumab treatment, leading to inactivation of Src with subsequent activation of the 
PI3K inhibitor PTEN, the protein product of the phosphatase and tensin homolog deleted 
on chromosome 10 gene. Thus, Herceptin activates the PTEN phosphatase, resulting in 
rapid Akt dephosphorylation and inhibits cell proliferation. 
 
Trastuzumab possesses not only targeting ability but also therapeutic effect compared to 
many targeted agents. The cytotoxic property enables trastuzumab to block proliferation 
and to promote cell death, which may be related in part to induction of an immune 
response (Stagg et al., 2008). Trastuzumab activated an antibody-dependent cellular 
cytotoxicity (ADCC) response in multiple breast cancer cell lines (Lewis et al., 1993; 
Cooley et al., 1999). Natural killer (NK) cells, expressing the Fc gamma receptor, are a 
principal immune cell type involved in ADCC. NK-mediated cell lysis is activated after 
trastuzumab binds to the Fc gamma receptor. Trastuzumab recruits immune effector cells 
that are responsible for antibody-dependent cytotoxicity, which has been put forward in 
preclinical models. Results of Clynes et al. (Clynes et al., 2007) showed that mice bearing 
BT474 HER-2-overexpressing xenografts demonstrated a tumor regression rate of 96% 
when treated with Herceptin. However, mice lacking the Fc receptor lost much of the 
protective effect of Herceptin, with only 29% tumor growth inhibition observed. Therefore, 
NK cells and ADCC are important contributors to the cytotoxic activity of Herceptin. 
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However, it should be noted that patients with advanced metastatic breast cancer are 
immuno-suppressed and may not be the optimal population to study. Additional studies 
are needed to better understand the importance of ADCC in mediating the response to 
Herceptin.  
 
Overexpression of HER2 in human cancer cells is associated with increased angiogenesis 
(Laughner et al., 2001).Trastuzumab might also play a role as an antiangiogenic agent, as 
it has been shown to induce normalization and regression of the vasculature in a human 
breast tumor model with HER2 positive (Izumi et al., 2002). Trastuzumab suppresses 
angiogenesis by both induction of antiangiogenic factors and repression of proangiogenic 
factors. Expression of multiple proangiogenic factors was reduced, while expression of 
antiangiogenic factors was increased in tumors with therapy of trastuzumab compared 
with control-treated tumors in vivo (Kos et al., 2003). Moreover, the combined use of 
trastuzumab and paclitaxel more effectively inhibited HER2-mediated angiogenesis than 
either treatment alone, which reflects more pronounced antitumor effects (Izumi et al., 
2002). Trastuzumab may also prevent ligation of HER2 with its ligand, by which 
apoptosis may be induced (Chang et al., 2003). 
 
2.6.2.2 Clinical efficacy of Herceptin 
The therapeutic efficacy and tolerability of trastuzumab have been investigated in various 
studies. The initial clinical trials investigating the safety of trastuzumab were performed 
on women with metastatic breast tumors overexpressing HER2. Results from Phase I and 
II trials in patients demonstrate that herceptin has an acceptable tolerability profile and 
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promising clinical efficacy in patients (Smith, 2001). A response rate of 15-35% was 
reported for trastuzumab monotherapy in MBC, showing that Herceptin has significant 
biostatic activity as a single agent (Cobleigh et al., 1999; Vogel et al., 2002). Cobleigh 
MA et al. (Cobleigh et al., 1999) reported a study in which the benefit of Herceptin as a 
single agent for MBC was evaluated. In the study, two hundred and twenty-two women 
were enrolled, of whom all were extensively pretreated and a quarter had received more 
than two prior therapies and two-thirds had received paclitaxel. Two hundred and thirteen 
patients received Herceptin and at 11 months, the overall response rate was found to be 
15% by an independent response evaluation committee. The median response duration 
was 8.4 months with an estimated median survival of 13 months. Treatment was well 
tolerated, with only two patients discontinuing therapy due to toxicity. In addition, the side 
effects attributable to Herceptin include fever, chills, pain, asthenia, nausea, vomiting and 
cardiac dysfunction were minimal. 
Herceptin has been approved for the first-line use in combination with chemotherapy. It 
has been found that Herceptin helps to increase the clinical benefit such as response rate, 
time to disease progression as well as overall survival of first-line chemotherapies such as 
paclitaxel, docetaxel, doxorubicin and cisplatin in patients with HER2 overexpressed 
MBC (Esteva et al., 2002; Romond et al., 2005; Hussain et al., 2007). Several studies 
have examined different trastuzumab-taxane combinations. For example, higher response 
rates have been reported for docetaxel, which yielded a 73% response rate in three phase 
II trials (Coudert BP 2006). An increased response rate of 50-80% was reported when 
trastuzumab was combined with single-agent cytotoxic chemotherapy in first line MBC 
(Piccart-Gebhart et al., 2005). Several studies have evaluated the role of Herceptin as 
preoperative therapy in patients with early-stage breast cancer. The greatest effect in vitro 
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and in vivo was seen with the combination of paclitaxel and Herceptin (Baselga et al., 
1998). The approved combination therapy indication for trastuzumab is with 3-weekly 
paclitaxel and after that both weekly paclitaxel and docetaxel regimens are widely used. A 
phase II study of preoperative Herceptin in combination with paclitaxel was reported by 
Burstein et al. (Burstein et al., 2003) and a pathologic complete response rate of 18% was 
found. Seidman et al. (Seidman et al., 2001) reported that women with MBC of HER2 
positive or negative response differently to Herceptin. In the study, patients were treated 
with standard-dose trastuzumab plus weekly paclitaxel (90 mg/m2). As expected, toxic 
effects were typical of single-agent paclitaxel, and cardiac function was preserved for at 
least a year. The response rate was 81% in patients who were HER2-positive by IHC 
evaluation and 43% in those who were HER2 negative. 
 
The success with Herceptin in treatment of metastatic breast cancer in combination with 
chemotherapy has inspired many more studies on developing effective targeted drug 
delivery systems. Therefore, to combine trastuzumab and chemotherapeutic agents such as 
paclitaxel and docetaxel for the treatment of HER2 overexpressed cancer has been 
suggested as a promising means of targeted chemotherapy 
 
2.6.3 Trastuzumab-functionalized nanoparticles 
Nanoparticles of biodegradable polymers as a drug delivery system have aroused 
continuous interest in recent years. Drug-loaded nanoparticles have considerable potential 
to provide an ideal solution for the major problems encountered in chemotherapy. It has 
been established that nanoparticles can become concentrated preferentially to tumors by 
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virtue of the EPR effect of the vasculature. Once accumulated at the target site, 
biodegradable polymeric nanoparticles can act as a local drug deposit and provide a source 
for a continuous supply of encapsulated therapeutic agent at the tumor site. The 
advantages of nanoparticles-based drug delivery systems include the sustained drug 
release, improved bioavailability, reduced systemic side effects and high capability to 
cross various physiological barriers (Krasnici et al., 2003; Lucarini et al., 2004). However 
the low selectivity of NPs towards the cancer cells hinders the advantages of the 
nanoparticle formulation for efficient chemotherapy as the therapeutic agents possess high 
toxicity. Therefore, it is necessary to develop effective therapies with specific effect in 
targeting the cancer cells.  
 
Effective drug targeting can be realized by the functionalization of nanoparticles with 
small molecule ligands such as folate (Kim et al., 2005) and thiamine (Oyewumi et al., 
2003), peptides such as Arginine-Glycine-Aspartic acid (RGD) (Meyer et al., 2006), sugar 
residues such as galactose (Jeong et al., 2005), antibodies and antibody fragments such as 
anti-HER2 (Cirstoiu-Hapca et al., 2007), nucleic acid aptamers such as anti-PSMA 
aptamer (Smith et al., 2007), as well as proteins such as transferrin (Bellocq et al., 2003). 
Among various ligands, trastuzuamb, the monoclonal antibody directed against HER2, is 
of great interest because it arises synergistic therapeutic effects with chemotherapy in 
addition to its targeting ability (Moasser, 2007). 
 
As have been stated in previous section, synergistic antitumor effects were found when 
trastuzumab is administrated in combination with chemotherapeutic agents such as 
paclitaxel, docetaxel and doxorubicin (Slamon et al., 2001; Burstein et al., 2003). Two 
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different targeting approaches have been reported by Nobs et al. (Nobs et al., 2006) for 
immunotargeting with trastuzumab conjugated to nanoparticles. One is a direct method 
using trastuzumab-labeled NPs and the other is a pretargeting method using the avidin-
biotin technology. Specific trastuzumab-labeled NPs binding to tumor cells produced a 
mean 10-fold or higher signal increase compared to control. The two-step method was 
evaluated in vitro by incubating SKOV-3 cells first with biotinylated mAbs followed by 
NPs. The relative fluorescence associated to the specific binding of NPs produced a 6-fold 
increase in flow cytometry signal compared to nonspecific binding, which suggested that 
trastuzumab-functionalized NPs might be a useful drug carrier for tumor targeting. 
 
Steinhauser et al. (Steinhauser et al., 2006) reported a time-dependent cell uptake study, in 
which a significant enrichment of trastuzumab-modified nanoparticles in 64.23% of 
HER2-positive SK-BR-3 cells was achieved compared to 3.59% in the case of for 30 min 
incubation. However, after incubation of 24 h the unspecific uptake of PEGylated 
nanoparticles without trastuzumab increased dramatically 39.62% compared to 
trastuzumab-modified nanoparticles 51.22%. Research on doxorubicin-Loaded 
trastuzumab-modified human serum albumin nanoparticles was reported by Anhorn et al. 
(Anhorn et al., 2008), which was the first demonstration of doxorubicin-loaded 
nanoparticles with a specific trastuzumab-based targeting of HER2 overexpressing breast 
cancer cells. There was a specific targeting with trastuzumab-functionalized doxorubicin-
loaded nanoparticles with a cellular binding of 73.80%, whereas doxorubicin-loaded 
nanoparticles without trastuzumab had a marginal cellular binding of 5.57%. By such a 
targeting system with trastuzumab as targeting ligands binding the HER2 receptor, higher 
drug levels in tumor tissue was achieved. Lee et al. (Lee et al., 2009) employed cationic 
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P(MDS-co-CES) micelles to delivery paclitaxel and Herceptin simultaneously, which is 
convenient to adjust the dosage of paclitaxel and Herceptin by simply altering the initial 
loading. Their results showed that cytotoxicity of paclitaxel was increased with co-
delivery of Herceptin, and the degree of increment in cytotoxicity depends on the level of 
HER2 expression. All these results indicate that the trastuzumab-functionalized 
nanoparticles can significantly promote targeted delivery of the drug to the corresponding 





Chapter 3 Trastuzumab-decorated biodegradable nanoparticles for 
targeted delivery of paclitaxel 
3.1 Introduction 
In this chapter, properties on the novel system of trastuzumab-decorated poly(D,L-lactide-
co-glycolide/montmorillonite (PLGA/MMT) nanoparticles for targeted delivery of 
paclitaxel was reported. The paclitaxel-loaded PLGA/MMT NPs were prepared by a 
modified solvent extraction/evaporation technique, in which the macromolecular 
emulsifier plays an important role in determining the particle size and the drug 
encapsulation efficiency as well as the cellular uptake of the nanoparticles and thus 
therapeutic effects of the encapsulated drug (Feng & Huang, 2001; Win & Feng, 2005).  
Trastuzumab was then coated on the NP surface through physical adhesion, which was 
employed to achieve a dual property of targeting and therapy for HER2-overexpressing 
cancer cells. In the nanoparticle formulation process, polyvinyl alcohol (PVA) was used as 
the emulsifier and MMT was also added in the aqueous phase as a co-emulsifier with a 
hope to treat the side effects of the formulated anticancer drug. MMT, a medical clay, is a 
potent detoxifier and could adsorb dietary toxins, bacterial toxins associated with 
gastrointestinal disturbance, hydrogen ions in acidosis, and metabolic toxins, which result 
in a host of common symptoms of the side effects such as nausea, vomiting, and diarrhea 
(Lee & Fu, 2003; Viseras et al., 2007).  
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Characterizations of paclitaxel-loaded PLGA/MMT NPs (Pac-PLGA/MMT NPs) and 
trastuzumab-decorated, paclitaxel-loaded PLGA/MMT NPs (Pac-PLGA/MMT-HER NPs) 
were conducted by various state-of-the-art techniques. The laser light scattering (LLS) 
was applied to measure particle size and size distribution, and field emission scanning 
electron microscopy (FESEM) was employed to study surface morphology. Surface 
charge was determined by Zeta potential analyzer. The drug encapsulation efficiency (EE) 
and in vitro drug release kinetics were measured by high-performance liquid 
chromatography (HPLC). Surface chemistry was analyzed by X-ray photoelectron 
spectroscopy (XPS). The structural integrity of the trastuzumab coated on the NP surface 
was verified through SDS-PAGE analysis. In vitro cellular uptake of fluorescent 
PLGA/MMT NPs with or without trastuzumab decoration was quantitatively measured by 
the microplate reader and visualized by confocal laser scanning microscopy (CLSM). 
Therapeutic effect of the paclitaxel formulated in the trastuzumab-decorated PLGA/MMT 
NPs was investigated in vitro by measuring the cytotoxicity of SK-BR-3 breast cancer 
cells, which was conducted in close comparison with that of the PLGA/MMT NP 
formulation with no trastuzumab decoration as well as with that of Taxol®. 
 
3.2 Materials and methods 
3.2.1 Materials 
Poly (DL-lactide-co-glycolide) (PLGA, L:G molar ratio: 50:50, Mw:40,000-75,000) and 
polyvinyl alcohol (PVA, Av. Mw 30,000–70,000) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Taxol® and Trastuzumab (Herceptin®) were obtained from National 
Cancer Center (NCC), Singapore. Paclitaxel of purity 99.8% was from Dabur India Ltd. 
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(India). Acetonitrile (HPLC grade) was from Fisher Scientific (NJ, USA). Sodium MMT 
(Closite Na+) was from Southern Clay Products Incorporation, USA. Dichloromethane 
(DCM, analytical grade) was from Merck (Germany). Fluorescence marker coumarin-6, 3-
(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), phosphate-buffered 
saline (PBS), penicillin-streptomycin solution, Triton® X-100 and Trypsin-EDTA were 
also from Sigma. McCoy’s 5A medium and fetal bovine serum (FBS) were from Gibco 
(Life Technologies, AG, Switzerland).  All solvents are of HPLC grade and all reagent 
water used in the laboratory was pretreated with the Milli-Q Plus System (Millipore 
Corporation, Bredford, USA). 
 
3.2.2 Preparation of nanoparticles 
Paclitaxel-loaded PLGA/MMT nanoparticles were prepared by a modified solvent 
extraction/evaporation method as described by Dong & Feng (Dong & Feng, 2005). In 
brief, an oil phase solution of 8 ml DCM containing 10 mg paclitaxel and 100 mg PLGA 
was slowly poured into 120 ml aqueous solution containing 2% w/v PVA and 0.042% w/v 
MMT. The resulted solution was sonicated 120 s by using a microtip probe sonicator with 
output power of 30 W. The formed emulsion was stirred overnight at room temperature to 
allow the organic solvent to evaporate. Hardened nanoparticles were then formed. The 
suspension was centrifuged, washed three times with deionized water, and freeze-dried. 
The fluorescent coumarin-6 loaded PLGA/MMT nanoparticles were prepared in the same 
way except 0.05% (w/v) coumarin-6 was encapsulated instead of paclitaxel. Then 0.5 ml 
trastuzumab of 100 µg/ml concentration in PBS was incubated with 0.5 ml resuspended 
nanoparticles overnight at room temperature to allow decoration of HER2 antibody on the 
 56
nanoparticle surface. Unconjugated antibody molecules were removed by twice 
centrifugation. 
 
3.2.3 Characterization of nanoparticles 
3.2.3.1 Size and size distribution 
The size and size distribution of paclitaxel-loaded PLGA/MMT NPs with and without 
trastuzumab decoration were measured by LLS (90 Plus Particle Sizer, Brookhaven 
Instruments, USA). The value was recorded as the mean of seven measurements. The size 
distribution is given by polydispersity index (PI, a value between 0 and 1). A PI of 1 
indicates large variations in particle size; a PI of 0 indicates no variation in particle size 
(an ideal monodisperse formulation). 
 
3.2.3.2 Surface morphology 
The surface morphology of the paclitaxel-loaded PLGA/MMT NPs with or without HER2 
antibody decoration was investigated by a field emission scanning electron microscopy 
system (FESEM, JEOL JSM-6700F, Japan). The samples were prepared by dripping a 
drop of the NP suspension onto the copper tape placed on the surface of the sample stub 
and dried overnight. The stub was coated with a platinum layer by the Auto Fine Platinum 




3.2.3.3 Surface charge 
The zeta potential, i.e. the surface charge of paclitaxel-loaded PLGA/MMT NPs with or 
without HER2 antibody decoration was detected by the laser Doppler anemometry (zeta 
plus, zeta potential analyzer, Brookhaven Corporation). The samples were diluted in 
deionized water before measurement.  The data were obtained with the average of seven 
measurements. 
 
3.2.3.4 Drug encapsulation efficiency 
The drug encapsulation efficiency (EE) of a drug delivery device is defined as the ratio of 
the amount of the drug successfully encapsulated in the device vs. that added in the 
preparation process. The analysis on the assay of paclitaxel can be determined by high 
performance liquid chromatography (HPLC, Agilent LC1100) at 227 nm UV wavelength. 
 
3.2.3.5 Thermal gravimetric analysis 
The content of MMT in the paclitaxel-loaded PLGA/MMT NPs was measured by 
Thermal-gravimetric Analyzer (TGA 2050). Given amount of the freeze-dried pure MMT 
or the paclitaxel-loaded PLGA/MMT NPs in the alumina crucible was heated from 50º to 
670 ºC ۫under nitrogen flow. The amount of MMT in the PLGA/MMT NPs can be 
determined from the weight loss. 
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3.2.3.6 Surface chemistry analysis 
For the nanoparticles to exhibit targeting ability, it is essential that HER2 antibody be 
expressed on the nanoparticle surface. X-ray Photoelectron Spectroscopy (XPS, RATOS 
AXIS His system, Shimadzu, Japan) was used to investigate the surface chemistry of the 
nanoparticles. The fixed transmission mode was utilized with a passing energy of 80eV 
and the binding energy spectrum was analyzed from 0 to 1,100 eV. 
 
3.2.3.7 SDS-PAGE analysis 
The primary structural integrity of HER2 antibody after conjugated onto the NP surface 
was detected by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
in comparison with the native HER2 antibody. All the gels were run under reducing 
conditions by using Mini-Protean II electrophoresis unit from BioRad at a constant 
voltage mode of 200V in a Tris/glycine/SDS buffer. The gels were stained with silver to 
reveal protein, destained and dried. 
 
3.2.4 In vitro drug release kinetics 
To study the impact of HER2 antibody decoration on the drug release kinetics from the 
PLGA/MMT NPs, in vitro drug release from both of the Pac-PLGA/MMT NPs and the 
Pac-PLGA/MMT-HER NPs were measured in triplicate. The drug-loaded NPs were 
dispersed in PBS (0.1M, pH 7.4) at 37 ºC in a centrifuge tube and then put in an orbital 
water bath shaking at 120 rpm at 37 ºC. At designated time intervals, the tube was taken 
out and centrifuged at a speed of 10,000 rpm for 15 min. The pellet was resuspended in 
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fresh PBS medium and placed back in the water bath for continuous release studies. The 
supernatant was collected and extracted with DCM. After removal of DCM by nitrogen 
flow, the deposited paclitaxel was dissolved in 1 ml of 50% water/50% acetonitrile. HPLC 
measurement was then carried out as described in the EE measurement section. The in 
vitro release of fluorescent markers from the coumarin-6 loaded nanoparticles was taken 
in a similar way except that the supernatant containing released fluorescence was 
measured by a microplate reader (GENios Tecan) with excitation wavelength at 430nm 
and emission wavelength at 485 nm. 
 
3.2.5 Cell cultures 
SK-BR-3 breast cancer cell line, which is of HER2 overexpression, and Caco-2 colon 
adeno carcinoma cell line, which is also HER2 positive, were purchased from American 
Type Culture Collection (ATCC, VA, USA). Both cell lines were cultured in 75 cm2 
flasks maintained at 37ºC in a humidified atmosphere with 5% CO2 (in air). Caco-2 cell 
line was grown in DMEM (Sigma) with 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin solution. SK-BR-3 cell line was grown in McCoy’s 5A (Invitrogen) media 
with 10% FBS. 
 
3.2.6 In vitro cellular uptake study 
3.2.6.1 Qualitative study through confocal laser scanning microscopy 
To give direct evidence that the coumarin-6-loaded NPs were internalized into the cells 
instead of just attaching to them, confocal laser scanning microscopy (CLSM) was used to 
visualize the internalization of the nanoparticles by SK-BR-3 cells. The nuclei of cells 
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were stained red with propidium iodide (PI) while the nanoparticles have fluorescence of 
green because of the coumarin-6 emission inside. SK-BR-3 cells were grown on the 
chambers (Lab-Teks Chambered Coverglass System) and maintained with 5% CO2 at 
37ºC. After 80% confluence, the medium was removed and the cell monolayers were 
incubated with 500 µl of the coumarin-6 loaded PLGA/MMT NPs suspension at the NP 
concentration 0.25 mg/ml for 2 h. Upon removal of the nanoparticle suspension and 
washing the cell monolayers thrice with PBS, the cells were fixed by an appropriate 
amount of ethanol and incubated for 20 min. Subsequently, propidium iodide (PI) was 
added to stain the nuclei after removal of ethanol. Finally, the cells were observed under 
CLSM (Leica TCS SP2) using a FITC filter. 
 
3.2.6.2 Quantitative study through microplate ready analysis 
Caco-2 cells and SK-BR-3 cells were seeded in 96-well black plates for quantitative study, 
respectively. After the cells reached 80% confluency, they were incubated with suspension 
of the coumarin-6 loaded PLGA/MMT NPs or PLGA/MMT-HER NPs at 37ºC at the NP 
concentration 0.25 mg/ml for 0.5, 1.0, 2.0, 4.0 h, respectively. For each sample, six wells 
were used for positive control and six wells for the NP sample. At the designated interval, 
the sample wells were washed three times with 50 µl cold PBS to eliminate traces of the 
NPs left in the wells and added with 100 µl culture medium. After that, 50 µl of 0.5% 
Triton X-100 in 0.2 N NaOH was added to the sample wells to lyse the cells. The 
fluorescence intensity of each well was measured by microplate reader (GENios Tecan) 
with excitation wavelength at 430 nm and emission wavelength at 485 nm. 
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3.2.7 In vitro cytotoxicity 
In vitro cytotoxicity study of the Pac-PLGA/MMT NPs, the Pac-PLGA/MMT-HER and 
Taxol® was quantitatively analyzed by the MTT assay, which is widely used to evaluate 
the cytotoxic activity of drugs or biomaterials. SK-BR-3 breast cancer cells were seeded in 
96-well plate (Costar, IL, USA) at a density of 4×104 cells/well. After the cells form 
monolayer, the medium was replaced by either the Pac-PLGA/MMT NP suspension, or 
the Pac-PLGA/MMT-HER NP suspension, or Taxol® at a designated equivalent paclitaxel 
concentration ranging from 0.025 to 50µg/ml. Meanwhile, the in vitro cytotoxicity study 
of placebo (without paclitaxel encapsulated) PLGA/MMT nanoparticles with/without 
trastuzumab decoration was also carried out to figure out the possible effects of the 
polymer and the targeting molecule on the in vitro therapeutic effect evaluation. Samples 
cultured with either formulation were seeded in six wells and the experiment was triply 
replicated. At designated time intervals, the medium was removed and the wells were 
washed with PBS. After washing, 100 µl MTT solution (0.5mg/ml) was then added to 
each well and incubated for 4 hours. After removal of culture solution, the precipitant was 
dissolved in 100 µl isopropanol before analyzed by microplate reader. Cell viability was 
expressed by the ratio between the fluorescence intensity of the cells incubated with NPs 
(or Taxol®) and that of the cells incubated with culture medium only (Feng & Mu, 2004). 
IC50, the drug concentration at which inhibition of 50% cell growth was observed in 
comparison with that of the control sample, was calculated from the cell viability versus 
the drug concentration curve at a given period (Sieuwerts et al., 1995). 
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3.3 Results and discussions 
3.3.1 Size, size distribution and drug encapsulation efficiency 
The size and size distribution along with the drug encapsulation efficiency of the Pac-
PLGA/MMT NPs and the Pac-PLGA/MMT-HER NPs are listed in Table 3-1, which 
shows that the two types NPs exhibited a size of around 300 nm diameter with 
polydispersity less than 0.120. In the process of NPs preparation, the surfactant plays an 
important role in determining the particle size by locating at the interface between the oil 
phase and the water phase so that stabilizes the formed nanoemulsion and prevents particle 
aggregation. As a co-emulsifier, MMT played an important role in stabilizing the 
emulsion by encapsulating the oil phase in the matrix network of the particles (Forni et al., 
1989). The trastuzumab on the surface significantly increased the nanoparticle size but had 
little effect on the drug encapsulation efficiency, which was found to be 51.6% for both 
NP formulations, which is slightly higher than that in the literature (Dong & Feng, 2005). 
 
3.3.2 Surface charge 
Paclitaxel-loaded PLGA/MMT nanoparticles are found negatively charged with an 
average value of –(35.07±1.68) mV, while trastuzumab was found positively charged at 
about +(8.45±0.74) mV, which means that the paclitaxel-loaded PLGA/MMT 
nanoparticles can be easily coated with trastuzumab by the electrostatic attraction between 
the two oppositely charged species. The surface charge of the Pac-PLGS/MMT-Her NPs 




3.3.3 Surface morphology 
Surface morphology of the paclitaxel-loaded PLGA/MMT nanoparticles with (Pac-
PLGA/MMT-HER NPs) or without (Pac-PLGA/MMT NPs) trastuzumab decoration was 
studied by field emission scanning electron microscope (FESEM). It can be found from 
Figure 3-1a that Pac-PLGA/MMT NPs exhibit smooth surface within the FESEM 
resolution level. In comparison, the Pac-PLGA/MMT-HER NPs (Figure 3-1b) are of 
blurry surface, which is caused by the surface decoration of trastuzumab. As the smooth 
surface may result in a slower drug release from the nanoparticles than that from those of 
rough surface, it can be predicted that the release of paclitaxel from the Pac-PLGA/MMT-
HER NPs would be faster than that of the Pac-PLGA/MMT NPs, which is proven to be 




Table 3-1 Characteristics of paclitaxel-loaded PLGA/MMT nanoparticles 




Pac-PLGA/MMT NPs 293.8±5.7 0.089 -35.07±1.68 51.6±2.3 
Pac-PLGA/MMT-HER NPs 312.3±8.2 0.116 -21.24±2.11 51.6±2.7 
PLGS: Poly(lactic-co-glycolic acid); MMT: Montmorillonite;  
NPs: Nanoparticles; EE: Encapsulation efficiency; 
Pac-PLGA/MMT NPs denote the paclitaxel-loaded PLGA/MMT nanoparticles;  











Figure 3-1 FESEM images of paclitaxel-loaded PLGA/MMT nanoparticles (a) without 
and (b) with trastuzumab decoration. 
 
3.3.4 Surface chemistry 
As XPS detects the presence of the various elements on the nanoparticle surface, it was 
important to identify a “marker” element that can be associated with trastuzumab. In the 
nanoparticle formulation, paclitaxel and trastuzumab are the only two elements which 
contain nitrogen. Therefore, nitrogen could be used as a “marker” to detect the presence of 
paclitaxel and trastuzumab on the nanoparticle surface. Figure 3-2 shows the XPS N1s 
region observed for the Pac-PLGA/MMT-HER NPs (the pink curve) and the Pac-
PLGA/MMT NPs (the black curve). Since no N1s signal could be observed from the black 
curve for the Pac-PLGA/MMT NPs, there should be no paclitaxel presented on the 
nanoparticle surface and all drug molecules are encapsulated inside the polymeric matrix. 
This is natural since both the drug and the polymer are hydrophobic. This agrees with 
earlier research on paclitaxel-loaded polymeric nanoparticles prepared with either 
phospholipids, or PVA, or TPGS as emulsifier (Feng & Huang, 2002). For the Pac-
a b
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PLGA/MMT-HER NPs, the pink curve shows one nitrogen peak, which is thus an 
evidence for existence of trastuzumab on the nanoparticle surface. The N1s XPS profile 
thus shows that trastuzumab has been successfully decorated on the drug-loaded 








Figure 3-2 XPS wide scan spectra of the paclitaxel-loaded PLGA/MMT nanoparticles 
with (the pink curve) or without (the blank curve) trastuzumab decoration. 
 
3.3.5 Stability of HER2 antibody 
Trastuzumab is a protein, which may become inactive due to irreversible denaturation or 
aggregation during the NP preparation process. The integrality of trastuzumab after coated 
on the NP surface was extracted and analyzed through SDS-PAGE experiment. Figure 3-3 
shows the SDS-PAGE analysis of the native trastuzumab and that extracted from the Pac-
PLGA/MMT-HER NPs, which was done under denatured conditions as the molecular 
weight of intact HER2-antibody is quite large (185 kDa). From the comparison of the 
native protein (Lane 2-4) and the protein coated on the PLGA-MMT NPs (Lanes 5-8), it 
can be concluded that the protein remains the same after being coated on the NP surface, 
Binding energy (ev) 
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 66
which also validates the feasibility of the Pac-PLGA/MMT-HER NPs for HER2 











Figure 3-3 SDS-PAGE of HER2 antibody: Lane 1: the molecular weight markers; Lanes 
2-4: the native HER2-antibody; Lanes 5-8: the Pac-PLGA/MMT-HER NPs coated with 
HER2-antibody. 
 
3.3.6 Thermal gravimetric analysis 
The content of MMT contained in the Pac-PLGA/MMT nanoparticles was estimated by 
thermal gravimetric analysis (TGA). From Figure 3-4, it can be seen that both of the pure 
MMT and the PLGA/MMT NPs exhibit a weight loss during the heating process. The 
weight loss of the pure MMT is found to be 12.6% and the weight loss of the PLGA/MMT 















Figure 3-4 Thermal gravimetric analysis of (a) MMT and (b) Pac-PLGA/MMT-HER NPs. 
 
3.3.7 In vitro drug release 
The in vitro paclitaxel release profiles of the Pac-PLGA/MMT NPs and Pac-PLGA/MMT-
HER NPs were shown in Figure 3-5a. Paclitaxel was allowed to be released from the 
drug-loaded nanoparticles in a pH 7.4 PBS buffer at 37 ºC. The insert is a magnification of 
the release curve in the first day, in which the measurement was made at 1, 3, 6 and 24 
hour, respectively. It can be found from Figure 3-5a that the Pac-PLGA/MMT NPs (solid 
line) and the Pac-PLGA/MMT-HER NPs (dotted line) exhibit similar biphasic drug 
release kinetics with an initial burst release up to 16.39±0.50% and 20.16±0.33% in the 
first day, followed by accumulative release of 63.32±1.77% and 68.20±1.26% after 30 
days, respectively. The drug release for the Pac-PLGA/MMT-HER NPs is significantly 
faster than for Pac-PLGA/MMT NPs. It seems that the surface modification of 
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nanoparticles provides a sink boundary condition for the drug diffusion within the 
polymeric matrix. 
 
In vitro fluorescence release from the coumarin-6 loaded PLGA/MMT NPs with/without 
trastuzumab decoration within 24 h was also carried out, which is shown in Figure 3-5b. 
Coumarin-6 has been widely used as a fluorescence marker in experiment of cellular 
uptake of nanoparticles because of its biocompatibility, high fluorescence activity, low 
dye loading (<0.5% w/w) and low leaking rate, which is to replace the drug in the 
nanoparticle formulation to visualize and measure the cellular uptake of the polymeric 
nanoparticles (Eley & Tirumalasetty, 2003). It can be found that the overall release of 
coumarin-6 within 24 h was 2.96±0.07% for the coumarin-6 loaded PLGA/MMT NPs 
(solid line) and 4.18±0.08% for NPs with trastuzumab decoration (dotted line). And within 
the first two hours, coumarin-6 was released only 1.73±0.06% and 2.57±0.08% from the 
coumarin-6 loaded PLGA/MMT NPs with/without trastuzumab decoration, respectively. 
Thus, it can be concluded that the release of fluorescence is much slower than paclitaxel 
from NPs. Thus, coumarin-6-encapsulated nanoparticles can be used to examine the 
cellular uptake effects since the fluorescent measurement is insignificant in comparison 
with that of the internalized NPs by the cells. This is in accordance with the study of Win 
& Feng (Win & Feng, 2005) that the release of coumarin-6 from the PLGA NPs was less 


























Figure 3-5 (a) In vitro drug release profiles of Pac-PLGA/MMT NPs (solid line) and Pac-
PLGA/MMT-HER NPs (dotted line) in pH 7.4 PBS buffer at 37 ºC. The insert is a 
magnification of the drug release in the first day, where the measurements were made at 1, 
3, 6 and 24 h, respectively. (b) In vitro release profiles of coumarin-6-loaded PLGA/MMT 
NPs (solid line) and PLGA/MMT-HER NPs (dotted line). Data represent mean ±SD, n=3. 
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3.3.8 Cellular uptake of nanoparticles 
Among various cell lines tested in the literature, SK-BR-3, a human breast cancer cell line, 
has the highest HER2 expression level (Wartlick et al., 2004) and Caco-2, a human colon 
adeno carcinoma cell line, is also found HER2 positive (Suen & Goss, 2000; Xu et al., 
2005). Thus these two cell lines were employed to investigate the cellular uptake of the 
Pac-PLGA/MMT NPs with/without trastuzumab decoration. Figure 3-6 shows the cellular 
uptake of the coumarin-6 loaded PLGA/MMT NPs with/without trastuzumab decoration, 
which was measured after 2 h incubation with Caco-2 cells and SK-BR-3 cells at 37ºC at 
0.125, 0.250, and 0.500 mg/ml nanoparticle concentration (n=6), respectively,. The 
cellular uptake of the nanoparticles was expressed as the fluorescence strength of the 
internalized nanoparticles related to that of the give nanoparticle concentration. It can be 
clearly found from Figure 3-6 that the trastuzumab decoration significantly increased the 
cellular uptake either by Caco-2 cells (Figure 3-6a) or by SK-BR-3 cells (Figure 3-6b). 
After 2 hour cell culture at 0.125 mg/ml NP concentration, the cellular uptake of the 
surface modified NPs by Caco-2 cells was 1.24-fold of that of the NPs without the surface 
modification, and the cellular uptake of the PLGA/MMT-HER NPs by SK-BR-3 cells was 









































Figure 3-6 Cellular uptake of coumarin-6-loaded PLGA/MMT NPs with/without 
trastuzumab decoration after 2 h incubation at 0.125, 0.25, 0.5 mg/ml nanoparticle 
concentration by (a) Caco-2 colon adeno carcinoma cells and (b) SK-BR-3 breast cancer 
cells, respectively. (n=6, p<0.05). 
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Besides the nanoparticle concentration, the incubation time is also an important factor to 
determine the cellular uptake efficiency. Figure 3-7 shows the cellular uptake of 
coumarin-6-loaded PLGA/MMT NPS with/without trastuzumab decoration by (a) Caco-2 
cells and (b) SK-BR-3 cells after 0.5, 1, 2, 4 h incubation at 0.125 mg/ml nanoparticle 
concentration at 37ºC (n=6), from which, it can be found that the longer incubation time, 
the higher cellular uptake efficiency.  
 
It should be noticed that cellular uptake of the fluorescent nanoparticles is expressed in 
this research as the fluorescence strength of the internalized fluorescent nanoparticles 
related to that of a given fluorescent nanoparticle concentration. The use of fluorescent 
markers in nanoparticle visualization, therefore, might lead to misinterpretation of 
nanoparticle uptake data due to the leaching or dissociation of fluorescent markers into the 
released medium and hence subsequently into the cells (Suh et al., 1998). It has been 
found that the liberated coumarin-6 molecules penetrates very well and thus falsifies the 
result by pretending enhanced nanoparticle uptake rates (Fujikawa et al., 2005). As has 
been discussed in previous section, the overall release of coumarin-6 from NPs was less 
than 5% within 24 h. Therefore, the fluorescent measurement of released coumarin-6 is 
insignificant in comparison with that of the internalized NPs by cells. Thus, coumarin-6-








































Figure 3-7 Cellular uptake of the coumarin-6-loaded PLGA/MMT NPs with/without 
HER2 antibody decoration after 0.5, 1, 2, 4 h incubation at 0.125 mg/ml nanoparticle 
concentration by (a) Caco-2 colon adeno carcinoma cells and (b) SK-BR-3 breast cancer 
cells (n=6, p<0.05). 
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3.3.9 Confocal microscopy 
Figure 3-8 shows confocal microscopic images of SK-BR-3 cell monolayer after 1 h 
culture with the Coumarin-6-loaded PLGA/MMT NPs with/without trastuzumab 
decoration at the nanoparticle concentration of 0.125 mg/ml at 37 ºC, which intuitively 
supports the previous quantitative measurements of the cellular uptake efficiency of the 
PLGA/MMT nanoparticles by showing strong fluorescence in the cytoplasm as well as in 
the nucleus. The images are made by sectioning function of CLSM, thus can evidence the 
internalization of the fluorescent nanoparticles. In comparison of the two images, it can be 
seen that the trastuzumab decoration does facilitate cellular uptake of the nanoparticles as 
more green fluorescence from cells incubated with NPs with trastuzumab (Figure 3-8b) 










Figure 3-8 Confocal laser scanning microscopy (CLSM) of SK-BR-3 breast cancer cells 
after 1h incubation with courmine-6 loaded (a) PLGA/MMT NPs and (b) PLGA/MMT-




It may also concern if the liberated coumarin-6 induces the fluorescence inside the cell or 
if it is due to the coumarin-6 loaded PLGA/MMT nanoparticles. As the release of the 
fluorescence from the NPs in the designated cell culture period is less than 3%, thus the 
effect of the liberated fluorescent markers on the fluorescent image could ne neglected. 
 
3.3.10 In vitro cytotoxicity 
Figure 3-9 shows the in vitro cytotoxicity of SK-BR-3 cells after 24 (Figure 3-9a), 48 
(Figure3-9b) and 72 h (Figure3-9c) culture with the paclitaxel formulated in Taxol®, the 
Pac-PLGA/MMT NPs and the Pac-PLGA/MMT-HER NPs at 0.025, 0.25, 2.5, 10, 25, 50 
µg/ml paclitaxel concentration (n=6), respectively. The viability was investigated by MTT 
assay. It can be seen that the in vitro viability of SK-BR-3 breast cancer cells decreases 
with the increase of the drug concentration as well as the incubation time. The Pac-
PLGA/MMT-HER NPs (shown as the third column in each cluster) exhibited the lowest 
viability (i.e. the highest cytotoxicity) among all three formulations, while the Pac-
PLGA/MMT NPs (shown as the second column in each cluster) exhibited a little bit lower 
or at least a comparable viability (or cytotoxicity) in comparison with Taxol®. It can thus 
be concluded that the Pac-PLGA/MMT NP formulation can increase the in vitro 
therapeutic effects in comparison with Taxol® and the Pac-PLGA/MMT-HER NP 
formulation does achieve significant targeting effects. 


























Figure 3-9 In vitro viability of SK-BR-3 breast cancer cells treated with paclitaxel 
formulated in Taxol®, Pac-PLGA/MMT NPs and Pac-PLGA/MMT-HER NPs at the same 
0.025, 0.25, 2.5, 10, 25, 50 µg/ml paclitaxel concentration  after (a) 24, (b) 48 and (c) 72 h 
culture, respectively (n=6). 
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Figure 3-10 shows a comparison of the in vitro SK-BR-3 cell viability of paclitaxel 
formulated in Taxol®, the Pac-PLGA/MMT NPs and the Pac-PLGA/MMT-HER NPs at 
the same 2.5 µg/ml paclitaxel concentration in 24, 48 and 72 h culture (n=6), respectively. 
Trastuzumab is a humanized monoclonal antibody for HER2-targeted breast cancer 
therapy and can thus exert a cytotoxic effect alone (Albanell et al., 1996). Therefore, the 
in vitro cytotoxicity study of placebo (without paclitaxel encapsulated) PLGA/MMT 
nanoparticles with/without trastuzumab decoration was also carried out and the result is 
also shown in Figure 3-10. The nanoparticle concentration was adjusted to be the same in 
all cases with nanoparticles involved. It can be seen from this figure that the in vitro 
viability of SK-BR-3 cells for the placebo PLGA/MMT nanoparticles without trastuzumab 
decoration (shown as the first column of each cluster) is 95.33±4.56%, 96.08±5.89% and 
92.54±4.34% for 24, 48 and 72 h, respectively, which means that the cytotoxicity of the 
placebo PLGA/MMT NPs on SK-BR-3 cancer cells is almost negligible.  
 
The in vitro viability of SK-BR-3 cells for the placebo nanoparticles with trastuzumab 
decoration (shown as the second column in each cluster) can be found to be 91.39±4.83%, 
87.67±4.40%, 83.23±4.85% for 24, 48 and 72 h, respectively, which proves that the 
trastuzumab decorated on the placebo PLGA/MMT NPs does have cytotoxic effects, and 
this must be considered when evaluating the cytotoxicity of paclitaxel formulated in the 
trastuzumab-decorated PLGA/MMT nanoparticles. The results agree qualitatively with 
that obtained in the literature, which determined the cytotoxic effectiveness of 
trastuzumab labeled with the 7.2-h half-life emitter 211At (Akabani et al., 2006). With 
this factor born in mind, however, it can still be concluded from Figure 3-10 that the 
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PLGA/MMT NP formulation of paclitaxel can achieve higher in vitro therapeutic effect 
than Taxol®; and the Pac-PLGA/MMT-HER NPs does achieve targeted drug delivery of 













Figure 3-10 In vitro viability of SK-BR-3 breast cancer cells treated with placebo 
PLGA/MMT NPS with/without trastuzumab decoration, paclitaxel formulated in Taxol®, 
Pac-PLGA/MMT NPs and Pac-PLGA/MMT-HER NPs 2.5 µg/ml drug concentration  
after 24, 48 and 72 h culture, respectively (n=6). 
 
 
The in vitro therapeutic effect and targeting effects of the various formulations of a drug 
can be quantitatively compared by IC50 at a given time period of cell culture, which is 
defined as the drug concentration at which 50% cells have been killed at that period. The 
IC50 values of paclitaxel formulated in the three formulations are given in Table 3-2, 
which was obtained by interpolation of the data shown in Fig 3-9. It can been seen from 
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Table 3-2 that (1) the PLGA/MMT NP formulation can have a lower IC50 than that of 
Taxol®, which is 97.2% of that for Taxol® after 24 cell culture, and (2) the Pac-
PLGA/MMT-HER NP formulation could be much more effective that the Pac-
PLGA/MMT NP formulation, having 12.74 times lower IC50 value in 24 h culture. The 
trastuzumab decoration did have significant targeting effects for the HER2 overexpressed 




In this chapter, research on poly(D,L-lactide-co-glycolide)/montmorillonite nanoparticles 
(PLGA/MMT NPs) for surface decoration by trastuzumab, the anti-HER2 antibody for 
targeted delivery of paclitaxel for breast cancer treatment was carried out. Such a 
nanoparticle system for drug delivery is multifunctional, which provides a way to 
formulate anticancer drugs with no use of harmful adjuvant, reduces the side effects of the 
formulated anticancer drug, promotes synergistic therapeutic effects, and achieves targeted 
Table 3-2 IC50 values of paclitaxel formulated in Taxol®, Pac-PLGA/MMT NPs and Pac-
PLGA/MMT-HER NPs after 24, 48, and 72 h incubation with SK-BR-3 breast cancer cells, 
respectively (n=3). 





Taxol 17.43±2.11 2.45±0.49 (5.17±0.833)×10-2 
Pac-PLGA/MMT NPs 16.94±2.28 2.37±0.43 (1.51±0.342)×10-2 
Pac-PLGA/MMT-HER NPs 1.33±0.27 (2.25±3.63)×10-4 (5.08±2.34)×10-4 
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delivery of the therapy. The paclitaxel-loaded PLGA/MMT NPs were prepared by a 
modified solvent extraction/evaporation technique, which were then decorated with 
trastuzumab. The effects of the surface decoration on particle size and polydispersity, 
surface morphology, drug encapsulation efficiency as well as the in vitro drug release 
profile were investigated. Both the Pac-PLGA/MMT NPs and the Pac-PLGA/MMT-HER 
NPs exhibited a biphasic drug release with moderate initial burst followed by sustained 
release profile while the latter showed a faster drug release than the former. Surface 
chemistry analyzed by XPS confirmed the presence of trastuzumab on the PLGA/MMT-
HER NP surface. SDS-PAGE showed that the stability and thus the activity of the 
antibody have been retained after the nanoparticle preparation process. Cellular uptake of 
the coumarin-6-loaded Pac-PLGA/MMT-HER NPs by Caco-2 colon adeno carcinoma 
cells and SK-BR-3 breast cancer cells were qualitatively accessed in comparison with that 
of the fluorescent Pac-PLGA/MMT-HER NPs. Internalization of the fluorescent 
PLGA/MMT NPs and the Pac-PLGA/MMT-HER NPs by SK-BR-3 cells was visualized 
by confocal laser scanning microscopy. Both of the quantitative and qualitative 
investigation showed that Pac-PLGA/MMT-HER NPs achieved significantly higher 
cellular uptake efficiency than the Pac-PLGA/MMT NPs. The results of in vitro 
cytotoxicity experiment on SK-BR-3 cells further proved the targeting effects of 
trastuzumab decoration on the PLGA/MMT nanoparticles. Judged by IC50 of SK-BR-3 
cells after 24 h culture, the therapeutic effects of Pac-PLGA/MMT-HER NP formulation 
could be 12.74 times higher than that of Pac-PLGA/MMT NP formulation and 13.11 
times higher than Taxol®. The trastuzumab-decorated PLGA/MMT NPs have potentials to 
be applied for targeted chemotherapy for HER2 positive cancer. 
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Chapter 4 Targeted delivery of docetaxel using trastuzumab-
functionalized nanoparticles of biodegradable copolymers 
4.1 Introduction 
In this chapter, a strategy of preparing nanoparticles of biodegradable copolymers (NPs) 
for targeted chemotherapy was developed, by which the targeting effect can be controlled. 
The NPs formulation consisted of a blend of two-component copolymers. One is 
poly(lactide)-D-α-tocopheryl polyethylene glycol succinate (PLA-TPGS), which is of 
desired hydrophobic-lipophilic balance (HLB) and can thus result in high drug 
encapsulation efficiency and high cellular adhesion/adsorption. Another is carboxyl 
group-terminated TPGS (TPGS-COOH), which plays the role as linker molecules when 
appearing on the NP surface. This provides a simple technique for conjugation of the 
molecular probes on the NP surface. Moreover, the targeting effect can be quantitatively 
controlled by adjusting the copolymer blend ratio. Docetaxel was used as a prototype drug, 
which is a hydrophobic anticancer drug and has excellent therapeutic effects for a wide 
spectrum of cancers such as breast cancer, non-small-cell lung cancer, ovarian cancer and 
head and neck cancer (Piccart et al., 1995; Trudeau et al., 1996). Docetaxel is semi-
synthetic analogue of paclitaxel, but more effective as an inhibitor of microtubule 
depolymerization due to its ability to alter tubulin processing within the cells (Gueritte-
Voegelein et al., 1991). Moreover, there is a synergistic antitumor effect when 
trastuzumab is combined with docetaxel (Slamon et al., 2001; Coudert et al., 2006). 
Therefore combination of trastuzumab and docetaxel for the treatment of HER2 
overexpressed breast cancer has been suggested as a promising means of targeted 
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chemotherapy. The docetaxel-loaded NPs of the copolymer blend were prepared by a 
modified solvent extraction/evaporation technique with TPGS as emulsifier. Then the NPs 
were functionalized with trastuzumab using established EDC/NHS chemistry. The formed 
trastuzumab-functionalized, docetaxel-loaded PLA-TPGS/TPGS-COOH NPs were 
characterized by various state-of-the-art techniques, which include laser light scattering 
(LLS) for size and size distribution, and zeta potential analyzer for surface charge; field 
emission scanning electron microscopy (FESEM) for surface morphology; and X-ray 
photoelectron spectroscopy (XPS) for surface chemistry. High-performance liquid 
chromatography (HPLC) was used to measure the drug encapsulation efficiency (EE) and 
the in vitro drug release kinetics. Since trastuzumab on the surface of the NPs can enhance 
cellular uptake via endocytosis by HER2-overexpressed cells, the in vitro cellular uptake 
of trastuzumab-functionalized NPs was investigated quantitatively by the microplate 
reader and visualized by confocal laser scanning microscopy (CLSM). The in vitro 
therapeutic effect of docetaxel encapsulated in the trastuzumab-functionalized NPs was 
investigated by measuring the cytotoxicity on SK-BR-3 breast cancer cells, which was 
conducted in close comparison with that of the NPs without trastuzumab as well as with 
that of Taxotere®. 
 
4.2 Materials and methods 
4.2.1 Materials 
Lactide (3,6-dimethyl-1,4-dioxane-2,5-dione, C6H8O4) was purchased from Aldrich. It 
was recrystallized twice with ethyl acetate before used. Vitamin E D-α-tocopheryl 
polyethylene glycol 1000 succinate (vitamin E TPGS or simply TPGS) was obtained from 
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Eastman Chemical company (USA). Stannous octoate (Sn(OOCC7H15)2), penicillin-
streptomycin solution, trypsin-EDTA solution, N,N’-dicyclohexylcarbodiimide (DCC), 4-
dimethylaminopyridine (DMAP), 1-ethyl-3-(3-dimethylamino) propyl carbodiimide 
(EDC), N-hydroxysuccinimide (NHS), glutaric acid, ethylene diamine, triethylamine, N-
Boc ethylenediamine and Dulbecco's Modified Eagle's Medium (DMEM) were obtained 
from Sigma-Aldrich (St. Louis, MO, USA). McCOY’s 5A Medium and fetal bovine 
serum (FBS) was purchased from Gibco (Life Technologies, AG, Switzerland). Easy-Titer 
Human IgG(H±L) assay kit was purchased from Pierce (Pierce-Biotechnology, USA). All 
chemicals used were HPLC grade, which includes dichloromethane (DCM) from Aldrich. 
Millipore water produced by the Milli-Q Plus System (Millipore Corporation, Breford, 
USA) was used in all the experiments. SK-BR-3 breast cancer cells and MCF-7 breast 
cancer cells were purchased from American Type Culture Collection (ATCC). Cell 
Counting Kit-8 was purchased from Dojindo (Maryland, USA). Taxotere® was from 
Sanofi-Aventis (Paris, France) and purchased through National University Hospital 
(Singapore). Herceptin® was from Roche (Switzerland) and purchased through National 
Cancer Center (Singapore). Docetaxel Anhydrous of purity 99.5% was from Jinhe Bio-
technology Co., Ltd (Shanghai China). 
 
4.2.2 Synthesis of PLA-TPGS and TPGS-COOH copolymers 
The copolymer PLA-TPGS of component ratio PLA/TPGS=88:12 (w/w) was synthesized 
from lactide and TPGS via ring opening polymerization with stannous octoate as a 
catalyst as described by Zhang & Feng (Zhang & Feng, 2006a). Briefly, weighted 
amounts of lactide, TPGS and 0.5% stannous octoate (in distilled toluene) were added into 
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an ampoule, which was then evacuated in liquid nitrogen. After 45 min, the ampoule was 
sealed by butane burner and reacted in silicone oil bath at 145 °C for 12 h. After reaction, 
DCM was added to the ampoule and the product was precipitated in excess cold methanol. 
After filtration, the final product was vacuum dried for 2 days and the synthesized PLA-
TPGS copolymer was characterized by 1H NMR. 
 
TPGS-COOH was synthesized as described (Zhang et al., 2007). In brief, TPGS was 
allowed to react with glutaric acid, DCC and DMAP at TPGS/glutaric 
acid/DCC/DMAP = 1:1:1:0.1 in stoichiometric molar ratio in DMSO under nitrogen 
atmosphere at room temperature. After 24 h, the product was filtered to remove N,N-
dicyclohexylurea (DCU), and then dialyzed against DMSO for 24 h to remove excess 
DCC, and against water for 24 h to remove DMSO. The final product was freeze-dried for 
two days. 
 
4.2.3 Preparation of nanoparticles 
Docetaxel-loaded nanoparticles of PLA–TPGS and TPGS-COOH blend were prepared by 
a modified solvent extraction/evaporation method. Four levels of the mass ratio between 
PLA–TPGS and TPGS-COOH were used in this research, which were 1:0, 9:1, 4:1 and 
2:1, for which the weight amounts of TPGS-COOH in the blend are thus 0%, 10%, 20% 
and 33.3%. In brief, 10 mg docetaxel and 100 mg of the PLA-TPGS/TPGS-COOH blend 
at various weight ratios were dissolved in 8 ml DCM. The formed solution was poured 
into 120 ml aqueous phase containing 0.03% (w/v) TPGS as emulsifier under gentle 
stirring, and sonicated at 25 W output for 120 s. The emulsion was evaporated overnight 
 85
and then centrifuged at 10,500 rpm for 20 min. The pellet was resuspended in water and 
freeze-dried for 2 days. Hereinafter, the docetaxel-loaded PLA-TPGS/TPGS-COOH NPs 
of 0%, 10%, 20% and 33.3% TPGS-COOH were termed NP0, NP10, NP20 and NP33, 
respectively and these NPs with no trastuzumab conjugated are called nude NPs in this 
article. 
 
Before trastuzumab conjugation, the docetaxel-loaded PLA-TPGS/TPGS-COOH NPs 
were first activated according to a procedure similar to that described in (Wuang et al., 
2008), where polypyrrole nanoparticles were synthesized to formulate Iron oxides (IOs) 
for targeted MRI imaging. In brief, 10 mg of PLA-TPGS/TPGS-COOH NPs were 
dispersed in 4 ml DI water followed by adding 20 mg of 1-ethyl-3-(3-dimethylamino)-
propyl cabodiimide (EDC), 8 mg of N-hydroxysuccinimide (NHS). One milligram of N-
Boc ethylenediamine was added to introduce amine groups to the NPs. The pH of the 
reaction mixture was adjusted to 8 with triethylamine. After 4 h of reaction at room 
temperature, the mixture was centrifuged, washed with DI water and dried under reduced 
pressure. Then the product was treated with trifluoroacetic acid (TFA) at 0 °C for 30 min 
to remove N-Boc protection. After evaporation of TFA, the product was wash with DI 
water and dried. Trastuzumab was then conjugated to the NPs using carbodiimide 
chemistry. The NPs were dispersed in 2 ml of 0.1 M PBS and placed in an ultrasonic bath 
for 30 min. Then 10 mg of NHS and 50 mg of EDC were added. After that 500 µl of 
trastuzumab (10 mg/ml) was added for reaction and triethylamine was used to adjust the 
pH of the reaction mixture to 8. After 4 h reaction at room temperature, the resulting 
product was centrifuged, washed with DI water and dried under reduced pressure. 
 86
Hereinafter, the docetaxel-loaded NPs prepared from 10%, 20% and 33.3% TPGS-COOH 
with trastuzumab conjugation were termed NP10-HER, NP20-HER and NP33-HER, 
respectively. The detailed scheme for preparation of nanoparticles is shown in Figure 4-1. 
 
The coumarin-6 loaded PLA-TPGS/TPGS-COOH NPs with/without trastuzumab 
conjugation were prepared in the same way as for the docetaxel-loaded NPs except that 
0.05% (w/v) coumarin-6 instead of docetaxel was used. The coumarin-6 loaded NPs were 











































Figure 4-1 Schematic description of the preparation of the trastuzumab-functionalized, 

































































DCC, glutaric acid, DMSO 
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4.2.4 Characterization of nanoparticles 
4.2.4.1 Size and size distribution 
The size and size distribution of the docetaxel-loaded PLA-TPGS/TPGS-COOH NPs were 
measured by laser light scattering (LLS) (90 Plus, Brookhaven Instruments, USA). The 
dried nanoparticles were suspended in DI water and sonicated for 2 min to prevent particle 
aggregation before measurement. The value was recorded as the mean of seven 
measurements and the size distribution is given by polydispersity index (PI, a value 
between 0 and 1). A PI of 1 indicates large variations in particle size and a PI of 0 
indicates no variation in particle size (an ideal monodisperse formulation). 
 
4.2.4.2 Surface charge 
The zeta potential, i.e. the surface charge of the docetaxel-loaded PLA-TPGS/TPGS-
COOH NPs was measured by the ZetaPlus zeta potential analyzer (Brookhaven 
Instruments Corporation). The samples were diluted in deionized water before 
measurement.  The data were obtained with the average of seven readings. 
 
4.2.4.3 Quantification of trastuzumab 
The amount of trastuzumab conjugated on NPs was quantified with the Easy-Titer Human 
IgG(H±L) assay kit (Pierce) (Wuang et al., 2008). Briefly, 20 µl of the sensitized beads 
provided in the kit was added to six wells in a 96-well plate (Costar, IL, USA). Then 20 µl 
of the sample was added into the appropriate wells containing the beads. The plate was 
mixed continuously on a plate mixer at a moderate-to-high speed setting for 5 min. After 
that, 100 µl of the blocking buffer was added to each well and the plate was mixed for 
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another 5 min. Then the plate was evaluated with a microplate reader by measuring the 
absorbance at 405 nm. The amount of trastuzumab was determined using a calibration 
curve prepared by standard solution of trastuzumab. 
 
4.2.4.4 Surface morphology 
The surface morphology of the docetaxel-loaded PLA-TPGS/TPGS-COOH NPs was 
investigated by a field emission scanning electron microscopy system (FESEM, JEOL 
JSM-6700F, Japan). The samples were prepared by dripping a drop of the NP suspension 
onto the copper tape placed on the surface of the sample stub and dried overnight. The 
stub was coated with a platinum layer by the Auto Fine Platinum Coater (JEOL, Tokyo, 
Japan) for 40 s before measuring. 
 
4.2.4.5 Surface chemistry 
X-ray photoelectron spectroscopy (XPS, RATOS AXIS His system, Shimadzu, Japan) 
was used to investigate the surface chemistry of the NPs. The fixed transmission mode 
was utilized with a passing energy of 80 eV and the binding energy spectrum was 
analyzed from 0 to 1100 eV.  
 
4.2.4.6 Drug encapsulation efficiency 
According to Mu & Feng (Mu & Feng, 2002), the drug encapsulation efficiency (EE) of a 
drug delivery device is defined as follows: 
100%
processn preparatioin  added drug ofAmount 
devicedelivery  drugin  edencapsulat drug ofAmount (%) ×=EE  
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The analysis of docetaxel can be determined by high performance liquid chromatography 
(HPLC, Agilent LC1100) at a UV/VIS detection wavelength of 230 nm (Musumeci et al., 
2006). Briefly, 3 mg of freeze-dried NPs were completely dissolved in 1 ml of DCM and 
the solvent was allowed to evaporate overnight. The residue was reconstituted in 1 ml 
mobile phase (45% acetonitrile: 5% methanol: 50% water) for analysis at the flow rate of 
1 ml/min. Drug encapsulation efficiency was calculated according the equation above and 
the measurement was done in triplicate. 
 
4.2.4.7 SDS-PAGE analysis 
The primary structural integrity of HER2 antibody after conjugated onto the NP surface 
was detected by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
in comparison with the native HER2 antibody and reference markers. All the gels were 
run under reducing conditions by using Mini-Protean II electrophoresis unit from BioRad 
at a constant voltage mode of 200V in a Tris/glycine/SDS buffer. The gels were stained 
with silver to reveal protein, destained and dried.  
 
4.2.5 In vitro drug release kinetics 
Briefly, 5 mg freeze-dried docetaxel-loaded NPs were put in a capped centrifuge tube and 
dispersed in 5 ml PBS (0.1 M, pH 7.4) containing 0.1% w/v Tween 80 to simulate the sink 
condition. The centrifuge tubes were put in an orbital water bath shaking at 120 rpm at 
37 °C. At the designated time intervals (1, 3, 6, 24 hours for the first day; 2, 3, 4, 5, 10, 15, 
20, 25 and 30 days), the tubes were taken out and centrifuged at 10,500 rpm for 15 min. 
The pellet was redispersed in fresh PBS medium and put back to the orbital water bath for 
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continued release study whilst the supernatant was collected and the released drug was 
then extracted with DCM. After evaporation of DCM by nitrogen flow, the deposited 
docetaxel was dissolved in mobile phase (45% acetonitrile: 5% methanol: 50% water) and 
HPLC measurement was carried out under the same conditions and settings as previously 
described in the EE measurement section. All samples were studied in triplicates. 
 
4.2.6 Cell cultures 
SK-BR-3 breast cancer cells and MCF-7 breast cancer cells purchased from American 
Type Culture Collection (ATCC, VA, USA) were used in this study. SK-BR-3 cells are 
known to have high expression of HER2, and MCF-7 cell line is characterized of 
moderate HER2 expression (Fiorio et al., 2008). Both cell lines were cultured in 75 cm2 
flasks maintained at 37 °C in a humidified atmosphere with 5% CO2. MCF-7 cell line was 
grown in DMEM with 10% FBS and 1% penicillin-streptomycin solution. SK-BR-3 cell 
line was grown in McCoy’s 5A media with 10% FBS. 
 
4.2.7 In vitro cellular uptake study 
4.2.7.1 Qualitative study: confocal laser scanning microscopy (CLSM) 
For qualitative study, MCF-7 cells and SK-BR-3 cells were seeded in chambered cover 
glasses system (LAB-TEK®, Nagle Nunc International, Naperville, IL, USA) and 
incubated at 37 °C in a humidified atmosphere with 5% CO2. After forming monolayer, 
the cells were washed with PBS. Then coumarin-6 loaded nanoparticle suspension (125 
µg/ml in medium) was added into the chambers and the cells were further incubated for 2 
h. The monolayer was washed three times with PBS and then fixed with 75% ethanol. 
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After washing with PBS, the nuclei of cells were stained by propidium iodide (PI) for 30 
min. The monolayer was washed twice with PBS and observed by confocal laser scanning 
microscopy (CLSM) (Zeiss LSM 410, Germany).  
 
4.2.7.2 Quantitative study: microplate reader analysis 
SK-BR-3, MCF-7 cells were seeded in 96-well black plates (Costar, IL, USA). After the 
cells reached 80% confluence, the medium was changed with the suspension of coumarin-
6-loaded NP20, NP20-HER at a nanoparticle concentration 125 µg/ml for 0.5, 1.0, 2.0, 4.0 
h incubation, respectively. For each sample, total 12 wells, were used. Among the 12 
wells, six wells were kept intact after incubation as positive control and the other six wells 
were used as samples for investigation. At designated time interval, the NP suspension of 
the sample wells was removed and the wells were washed with 50 µl of PBS for three 
times. After that, 100 µl culture medium was added to the sample wells followed by 50 µl 
of 0.5% Triton X-100 in 0.2 N NaOH to lyse the cells. The fluorescence intensity present 
in each well was then measured by microplate reader (GENios Tecan) with excitation 
wavelength at 430 nm and emission wavelength at 485 nm. The cellular uptake was 
expressed as the percentage of the fluorescence of the sample wells versus that of the 
positive control solution. 
 
4.2.8 In vitro cell cytotoxicity 
SK-BR-3 breast cancer cells and MCF-7 breast cancer cells were incubated in transparent 
96-well plates (Costar, IL, USA) as previously described. After the cells formed 
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monolayer, the medium was replaced by either NP formulation with/without trastuzumab 
functionalization or Taxotere® solutions at a 25 µg/ml docetaxel concentration in medium. 
The in vitro cytotoxicity of placebo nanoparticles with/without trastuzumab 
functionalization was also studied in comparison with docetaxel-loaded nanoparticles. At 
given time intervals (24, 48 and 72 h), the cultured cells were analyzed for cell viability 
with Cell Counting Kit-8 (CCK-8) assay (Dojindo, Maryland, USA). After removing the 
drug or NPs contained medium, the wells were added with 100 µl of medium and 10 µl of 
the CCK-8 assay. Then the plate was shaked gently and incubated in darkness for two 
hours. After incubation, the absorbance at 450 nm of the sample was measured by 
microplate reader (GENios Tecan, Switzerland). The cell viability was expressed by the 
ratio of the measured intensity of the sample wells and that of the control wells incubated 
with medium only. 
 
4.3 Results and discussions 
4.3.1 Characterization of PLA-TPGS copolymer 
The structure of the synthesized PLA-TPGS copolymer was detected by 1H NMR in 
CDCl3. Figure 4-2 shows the typical 1H NMR spectra of the synthesized PLA-TPGS 
copolymer. The signals at 5.2 and 1.69 ppm were assigned to the –CH protons and methyl 
protons –CH3 of PLA segment, respectively. The peak at 3.65 ppm was assigned to the –
CH2 protons of PEO part of TPGS. Formation of the PLA-TPGS copolymer was verified 
as the CH protons peak of the copolymer, which was located at 5.2 ppm as compared to 
5.07 ppm for that of the lactide monomer (Zhang & Feng, 2006a). The molecular weight 
of synthesized PLA-TPGS was calculated by the ratio between the peak areas at 5.2 and 
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3.65 ppm. The number-averaged molecular weight (Mn) of the PLA-TPGS copolymer 












Figure 4-2 Typical 1H NMR spectra of PLA-TPGS copolymer in CDCl3. 
 
4.3.2 Size & size distribution 
The docetaxel-loaded PLA-TPGS/TPGS-COOH nanoparticles were prepared with TPGS 
added as surfactant in the fabrication process, which is efficient to stabilize the formed 
nanoemulsion, prevent particles aggregation and thus produce NPs of small polydispersity 
(Win & Feng, 2006). Particle size, polydispersity, zeta-potential and drug encapsulation 
efficiency of the docetaxel-loaded PLA-TPGS/TPGS-COOH NPs of 0, 10, 20 and 33.3% 
TPGS-COOH with/without trastuzumab surface modification are listed in Table 4-1, from 
which it can be found that the NPs of all formulations in this study were of with a size of 






Surface modification of the NPs by trastuzumab slightly increased the particle size and 
polydispersity, which, however, seem not affected by the amount of trastuzumab on the 
NP surface. And NPs of around 200 nm in diameter seem to be appropriate to be used as 
drug carrier, which would be uptaken by the diseased cells through a mechanism called 
endocytosis, in which the individual nanoparticles would first adhere to the cell surface 
and bend a small piece of the lipid bilayer membrane. The nanoparticles would then be 
enveloped and engulfed into the cytoplasm. In this process, the surface energy of the NPs 
is sacrificed to provide the bending energy. Too small NPs would not have enough surface 
energy to complete the cell membrane bending process. Moreover, too small NPs would 
result in too small drug encapsulation efficiency and cause too fast drug release (Feng, 
2006; Decuzzi & Ferrari, 2007).  
 
4.3.3 Quantification of trastuzumab 
The amount of trastuzumab conjugated on NP surface was evaluated with the Easy-Titer 
Human IgG(H±L) assay kit (Pierce) and the result was shown in Table 4-1. It can be 
found that the amount of trastuzumab was 0.68±0.03, 0.93±0.05 and 1.07±0.05 µg for per 
mg NP10-HER, NP20-HER and NP33-HER, respectively. This means the amount of 
TPGS-COOH added in NP fabrication affected the amount of trastuzumab conjugated on 





4.3.4 Surface charge 
Zeta potential is an important factor to determine the stability of the NPs in dispersion. 
Surface charge also plays important role in the interaction between the cell membrane and 
the NPs. Low absolute value of the zeta-potential implicates colloidal instability, which 
could lead to aggregation of the NPs in dispersion. High absolute value of the zeta 
potential indicates high surface charge of the NPs, which leads to strong repellent 
interactions among the NPs in dispersion and thus high stability. It can be seen from Table 
4-1 that the zeta potential of docetaxel-loaded PLA-TPGS/TPGS-COOH NPs without 
Table 4-1 Characteristics of docetaxel-loaded, trastuzumab-functionalized nanoparticles 
of PLA-TPGS and TPGS-COOH blend at various component ratios. 
 







NP0 301.8±9.5 0.143±0.02 -42.73±3.88 54.7±4.73  
NP10 294.7±9.2 0.151±0.03 -41.68±4.12 55.8±4.62  
NP10-HER 308.5±9.0 0.202±0.03 -32.25±2.95 54.5±6.25 0.68±0.03 
NP20 286.2±10.2 0.156±0.03 -40.33±4.01 57.4±4.19  
NP20-HER 305.7±11.8 0.175±0.05 -25.08±1.15 55.7±5.75 0.93±0.05 
NP33 292.5±9.8 0.121±0.03 -41.50±3.28 48.2±4.03  
NP33-HER 311.2±9.4 0.155±0.04 -23.94±2.09 47.5±4.58 1.07±0.05 
PLA-TPGS: poly(lactide)-D-α-tocopheryl polyethylene glycol succinate; TPGS-
COOH: carboxyl group-terminated TPGS; EE: Encapsulation efficiency; NP0, NP10, 
NP20, NP33 denote the NPs of 0%, 10%, 20%, 33.3% of TPGS–COOH in the 
copolymer blend, i.e. the NPs of PLA–TPGS/TPGS–COOH blend at weight ratio 1:0, 
9:1, 4:1 and 2:1, respectively. NP10-HER, NP20-HER and NP33-HER refer to the NPs 
with trastuzumab conjugated on the surface of NP10, NP20 and NP33, respectively. 
 97
trastuzumab modification was found to be around -40 mV, indicating the nanoparticle 
dispersion is stable. The absolute values of zeta potential for trastuzumab-functionalized 
NPs are lower than those without trastuzumab on NP surface and the more the 
trastuzumab on the surface, the lower the absolute values would be resulted.  
 
4.3.5 Drug encapsulation efficiency 
The drug encapsulation efficiency (EE) of the docetaxel-loaded PLA-TPGS/TPGS-COOH 
NPs is also included in Table 4-1, from which it can be found that the component ratio 
between PLA-TPGS and TPGS-COOH played an important role in affecting the EE of the 
NPs. For example, the EE of NP20, which contains 20% TPGS-COOH, is the highest 
among all the NPs. Either lower or higher content of TPGS-COOH in the polymeric 
matrix may cause lower EE. Surface decoration should increase the EE in general since it 
would decrease the drug diffusion from the NPs in the preparation process. However, drug 
diffusion from the NPs should also depend in the porosity of the NP matrix. The porosity 
of the polymeric matrix would be high if too much TPGS-COOH was added, which would 
speed the drug diffusion from the NPs in the preparation process. 
 
4.3.6 Surface morphology of nanoparticles 
Surface morphology of the docetaxel-loaded PLA-TPGS/TPGS-COOH NPs was studied 
by field emission scanning electron microscope (FESEM). The FESEM images of NP20 
and NP20-HER were shown in Figure 4-3. The docetaxel-loaded NPs without 
trastuzumab-modification were found spherical in shape with smooth surface within the 
FESEM resolution level and the size was around 300 nm, which is consistent with the 
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result determined by the laser light scattering. Compared with NP20, the NP20-HER was 
found of more blurry surface and there seemed to be adhesion between the NPs, which 









Figure 4-3 FESEM images of (a) docetaxel-loaded nanoparticles of PLA-TPGS (80%) and  
TPGS-COOH (20%) copolymer blend (NP20) and (b) trastuzumab-functionalized, 
docetaxel-loaded nanoparticles of PLA-TPGS (80%) and TPGS-COOH (20%) copolymer 
blends (NP20-HER). 
 
4.3.7 Surface chemistry 
X-ray photoelectron spectroscopy (XPS) was applied to study the surface chemistry of the 
docetaxel-loaded PLA-TPGS/TPGS-COOH NPs with/without surface modification. 
Figure 4-4 shows the XPS wide scan spectrum of the NPs of various component-
copolymer blend ratios. PLA-TPGS and TPGS-COOH do not contain any nitrogen atoms, 
while docetaxel and trastuzumab do. Therefore, nitrogen could be used as a ‘marker’ to 
detect the presence of docetaxel and trastuzumab on the NP surface. It can be seen from 
third spectrum from the top (For NP20) in Figure 4-4 that there is no N 1s signal at the 
397.6 eV binding energy position, which means there are no docetaxel molecules on the 
ba 
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NP surface (Beshkov et al., 2008). This agrees with the earlier research on paclitaxel-
loaded polymeric NPs prepared with either phospholipids, PVA or TPGS as emulsifier 
(Feng & Huang, 2001). From the second spectrum from the top (for NP20-HER), however, 
the nitrogen peak at the 397.6 eV binding energy position (circled in the figure) must 
come from trastuzumab, which confirms the successful conjugation of trastuzumab on the 
NP surface. For NP20-HER, the XPS spectrum shows one nitrogen peak, which can 
confirm the successful conjugation of trastuzumab on the NP surface. It can be found from 
a close comparison of the XPS spectra among NP10-HER, NP20-HER and NP33-HER 
that there was an increase tendency in the percentage of the N 1s region as the more 
TPGS-COOH is included in the polymeric matrix, which means more trastuzumab could 











Figure 4-4 The X-ray photoelectron spectroscopy (XPS) wide scan spectra of the 
docetaxel-loaded PLA-TPGS/TPGS-COOH nanoparticles. 
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4.3.8 Stability of HER2 antibody 
The integrality of HER2 antibody (trastuzumab) conjugated onto the NP surface was 
analyzed through SDS-PAGE experiment in comparison with the native antibody. 
Trastuzumab was extracted from NP20-HER and the result was shown in Figure 4-5, in 
which the antibody extracted from NP20-HER (lane 4-7) remains the same as the native 
antibody (lane 2-3). Thus, it can be concluded that the antibody conjugated on NP surface 
remains almost the same in structure as the native one, which can thus validate the 
feasibility of the targeting property of trastuzumab-functionalized NPs on HER2-













Figure 4-5 SDS-PAGE analysis of HER2 antibody: lane 1 is for the molecular weight 




4.3.9 In vitro drug release kinetics 
Figure 4-6a shows the 30-day in vitro release profiles of docetaxel from the drug-loaded 
PLA-TPGS/TPGS-COOH NPs with/without surface modification and Figure 4-6b shows 
the in vitro drug release curves in the first day, in which the measurements were made at 1, 
3, 6 and 24 h, respectively. Docetaxel was released from the NPs in a pH 7.4 PBS buffer 
at 37 °C. From Figure 4-6a, it can be found that docetaxel was released in a biphasic style 
with an initial burst and subsequent accumulative release. Figure 4-6b shows that the 
initial burst of NP0, NP10-HER, NP20, NP20-HER and NP33-HER within the first day is 
22.16±0.65%, 23.85±2.28, 24.21±1.53%, 25.67±2.25% and 26.72±2.03%, and the 30-day 
cumulative drug release of these NPs is 59.11±1.88%, 68.15±2.74%, 61.27±2.15%, 
68.28±3.55% and 71.82±3.18%, respectively.  It is obvious that the drug release of NP20-
HER is significantly faster than that of NP20, in other words, the surface modification 
significantly accelerated the drug release. This can be explained by effects of the surface 
modification on the surface morphology, which makes the NPs blurry and thus increases 
the surface area, which increases the speed at which the drug is released from the NPs 
(Figure 4-3). Comparing the release profiles of NP0 and NP20 in Figure 4-6, it can also be 
found that the drug release from NP20 was faster than from NP0. This can be explained 
by the higher porosity of the polymeric matrix caused by TPGS-COOH being more 
hydrophilic than PLA-TPGS, which assists the drug diffusion from the NPs as described 
previously. This trend can also be observed from the drug-release profiles of NP10-HER, 
























Figure 4-6 In vitro drug release profiles of docetaxel-loaded PLA-TPGS/TPGS-COOH 
nanoparticles with/without trastuzumab-functionalization within (a) 30 days and (b) the 
first day, where the measurements were made at 1, 3, 6 and 24 h, respectively. Each point 







4.3.10 Cellular uptake of nanoparticles 
4.3.10.1 Qualitative study 
The MCF-7 breast adenocarcinoma cells show moderate HER2 overexpress on their 
surface and the SK-BR-3 breast adenocarcinoma cells highly overexpress HER2. The 
targeting effect of the trastuzumab-functionalized NPs can thus be evaluated by employing 
these two cells lines to investigate the cellular uptake of coumarin-6-loaded NPs. Figure 4-
7 shows confocal microscopic images of SK-BR-3 cells treated with coumarin-6-loaded 
NP20 (Figure 4-7a), SK-BR-3 cells treated with coumarin-6-loaded NP20-HER (Figure 4-
7b), MCF-7 cells treated with coumarin-6-loaded NP20 (Figure 4-7c) and MCF-7 cells 
treated with Coumarin-6-loaded NP20-HER (Figure 4-7d) for 2 h at 125 µg/ml NP 
concentration at 37 ºC. The images were obtained from the sectioning function of CLSM 
and thus demonstrate the internalization of the fluorescent NPs. The nuclei of cells were 
stained by propidium iodide (PI), and the coumarin-6-loaded NPs (green) in the cytoplasm 
were visualized by overlaying images that were obtained by fluorescein isothiocyanate 
(FITC) filter and PI filter. When comparing Figure 4-7a&b for SK-BR-3 cells of high 
HER2 overexpression, it can be seen that trastuzumab conjugation facilitates cellular 
uptake of the NPs as more green fluorescence could be observed from Figure 4-7b than 
from Figure 4-7a.   
 
To further confirm the targeting effect of trastuzumab-functionalized NPs, MCF-7 cells, 
which have moderate HER2 expression, were imaged under similar conditions. The 
reduced uptake of coumarin-6-loaded NP20-HER by MCF-7 cells is clearly shown in 
Figure 4-7d when compared with Figure 4-7b for SK-BR-3 cells. The CLSM image 
indeed shows the successful targeting effects of trastuzumab-functionalized NPs to cells 
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Figure 4-7 Confocal microscopic images of (a) SK-BR-3 cells after 2 h incubation with 
coumarin-6-loaded NP20, (b) SK-BR-3 cells after 2 h incubation with coumarin-6-loaded 
NP20-HER, (c) MCF7 cells after 2 h incubation with coumarin-6-loaded NP20 and (d) 
MCF-7 cells after 2 h incubation with coumarin-6-loaded NP20-HER. All nanoparticles 







It should be noticed that the control used in the cellular uptake experiment was the 
suspension of the coumarin-6-loaded NPs at the same NP concentration, which represents 
100% if they all could be internalized into the cells. And the fluorescence observed from 
the cells after incubation with the NP suspension was from the NPs but not from the 
coumarin-6 molecules released from the NPs in the culture period, which has been stated 
in the research stated in previous chapter. 
 
4.3.10.2 Quantitative study 
Figure 4-8 shows the cellular uptake efficiency of coumarin-6-loaded NP20 and NP20-
HER by SK-BR-3 breast cancer cells and MCF-7 breast cancer cells at the same 125 
µg/ml NP concentration for 0.5, 1, 2 and 4 h, respectively. It can be seen from Figure 4-8 
that NP20-HER demonstrated much higher cellular uptake efficiency for both of MCF-7 
and SK-BR-3 cells than the NP20. For example, it can be found from Fig 4-8a that NP20-
HER achieved 1.36-, 1.33-, 1.31-, and 1.28-fold cellular uptake efficiency of that of NP20 
after 0.5, 1, 2 and 4 h incubation with SK-BR-3 cells, respectively. However, Figure 4-8b 
shows that NP20-HER showed 1.21-, 1.17-, 1.15-, and 1.17-fold cellular uptake efficiency 
of that for NP20 after 0.5, 1, 2 and 4 h incubation with MCF-7 cells, respectively. Thus, 
NP20-HER showed 1.12-, 1.14-, 1.14-, and 1.09-fold targeting effect for SK-BR-3 cancer 
cells (of high HER2 overexpression) of that for MCF-7 breast cancer cells (of moderate 























Figure 4-8 Cellular uptake efficiency of coumarin-6-loaded NPs after 0.5, 1, 2 and 4 h 
incubation at 125 µg/ml NP concentration by (a) MCF-7 breast cancer cells and (b) SK-
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The first group in Figure 4-8b shows that the cellular uptake efficiency by SK-BR-3 cells 
was 38.6 for naked NPs, and 52.5 for trastuzumab-functionalized NPs within 30 min 
incubation, respectively. This demonstrates that in such a short incubation period, the 
uptake of trastuzumab-functionalized NPs was enhanced in comparison with the cellular 
uptake of the naked NPs, which is in accordance with literature (Steinhauser et al., 2006; 
Spankuch et al., 2008). Moreover, Figure 4-8 clearly shows that the cellular uptake 
depends on the incubation time and the longer the incubation time, the higher cellular 
uptake efficiency that was achieved. Similar trends were also found in the work presented 
in previous chapter, where trastuzumab was physically attached on the PLGA/MMT NPs 
for targeted delivery of paclitaxel. 
 
4.3.11 In vitro cytotoxicity 
Figure 4-9 & Table 4-2 show the in vitro viability of MCF-7 and SK-BR-3 breast cancer 
cells treated with placebo NPs with (blank-NP20-HER) and without (blank-NP20) 
trastuzumab conjugation, Taxotere® and docetaxel-loaded PLA-TPGS/TPGS-COOH NPs 
of 20% TPGS-COOH with (NP20-HER) and without (NP20) trastuzumab conjugation at 
25 µg/ml docetaxel concentration after 24, 48 and 72 h treatment, respectively (n=6). The 
results are shown as cell viability. The sum of viability and mortality is always 100%. A 
concentration of 25 µg/ml docetaxel was chosen because the IC50 of the MCF-7 breast 
cancer cells has been found to be 13.2 µM, in other words, 10.7 µg/ml (Fite et al., 2007). 
The corresponding data of the in vitro viability are also listed in Table 4-2 to facilitate a 
quantitative comparison. From Figure 4-9 & Table 4-2, it can be clearly seen that the 
viability for both cell lines decreased as the incubation time increased, which means the 
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longer the culture time, the higher the cytotoxicity. Besides this, the following conclusions 
can be obtained: 
 
(a) In Figure 4-9a, the first column of each group for blank-NP20 for MCF-7 cells 
demonstrates that the viability for placebo PLA-TPGS/TPGS-COOH NPs without 
trastuzumab-functionalized was 96.1±2.6%, 95.5±3.8% and 94.8±5.2% after 24, 48 and 
72 h incubation, respectively. Similar results can be found from Figure 4-9b that the 
viability of SK-BR-3 cells for placebo NPs without trastuzumab-functionalized was 
98.4±4.0%, 95.5±5.7 and 95.7±4.2% after 24, 48 and 72 h incubation, respectively. This 
means that the placebo PLA-TPGS/TPGS-COOH NPs have high biocompatibility with 
fractional cytotoxicity. 
 
(b) The second column of each group shows the cell viability of placebo PLA-
TPGS/TPGS-COOH NPs with trastuzumab-functionalization (Blank-NP20-HER). In 
Figure 4-9a, the viability of MCF-7 cells is 90.3±3.3%, 85.3±4.8% and 78.7±5.2% after 
24, 48 and 72 h treatment, respectively. In Figure 4-9b, however, the viability of SK-BR-3 
cells is slightly lower: 88.2±5.1%, 80.3±6.6% and 75.3±4.3% for 24, 48 and 72 h, 
respectively. The results clear show the targeting effects of the trastuzumab-functionalized 
NPs for breast cancer cells that overexpress HER2. 
 
(c) The third column of each group shows the viability of two breast cancer cell lines after 
24, 48 and 72 h treatment with Taxotere, which is 56.9±2.6%, 51.3±4.3% and 43.2±3.6% 
for MCF-7 cells and 61.3±1.9%, 57.8±2.1 and 41.4±1.4% for SK-BR-3 cells. This 
suggests that Taxotere may be more effective for MCF-7 breast cancer cells than for SK-
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BR-3 breast cancer cells over a short time period (24 and 48 h), and the effect may 
become inverse over a longer time period (72 h). By contrast, the in vitro viability shown 
in the fourth column of each group in Figure 4-9 is 55.8±3.1%, 43.2±3.0% and 15.5±3.4% 
for MCF-7 cells and 62.7±2.8%, 51.9±6.1% and 16.4±3.2% for SK-BR-3 cells after 24, 48 
and 72 h treatment, respectively. This indicates that when evaluated by cellular mortality, 
the NP formulation has a comparable in vitro therapeutic effect (1.025-fold for MCF-7 
cells and 0.964-fold for SK-BR-3 cells) with Taxotere after 24 h cell culture. However, the 
NP formulation of docetaxel would be 1.166- and 1.486-fold more effective for MCF-7 
cells and 1.140- and 1.427-fold more effective for SK-BR-3 cells than Taxotere after 48 
and 72 h treatment, respectively. This may be attributed to the sustainable drug-release 
manner of the NP formulation. 
 
(d) The fifth column of every group shows the viability of the MCF-7 and SK-BR-3 breast 
cancer cell lines after 24, 48 and 72 h treatment with NP20-HER, which is 46.3±2.7%, 
31.0±3.2% and 9.4±3.1% for MCF-7 cells and 36.7±1.3%, 9.2±2.0% and 5.9±2.5% for 
SK-BR-3 cells, respectively. It can thus be concluded that when judged by cellular 
mortality, the trastuzumab-functionalized NP formulation can be 1.215-, 1.215- and 
1.073-fold more effective for MCF-7 cells and 1.697-, 1.886- and 1.126-fold more 
effective for SK-BR-3 cells than the NP formulation without trastuzumab-
functionalization after 24, 48 and 72 g treatment, respectively. The targeting effects of 
trastuzumab functionalization thus showed 39.7%, 55.2% and 4.9% higher cancer cell 




(e) The combination of the advantages of the PLA-TPGS/TPGS-COOH NP formulation 
and the trastuzumab functionalization indicates that the trastuzumab-functionalized NP 
formulation could be 1.245-, 1.417- and 1.594-fold for MCF-7 cells and 1.635-, 2.150- 











Table 4-2 In vitro viability of MCF-7 and SK-BR-3 breast cancer cells treated with 
placebo NPs (Blank-NP20 and Blank20-HER), Taxotere® and docetaxel-loaded NPs 
(NP20 and NP20-HER) at 25 µg/ml docetaxel concentration after 24, 48, 72 h treatment, 
respectively (n=6). 
 24 h 48 h 72 h 
 MCF-7 SK-BR-3 MCF-7 SK-BR-3 MCF-7 SK-BR-3 
Blank-NP20 96.1±2.6 98.4±4.0 95.5±3.8 95.5±5.7 94.8±5.2 95.7±4.2 
Blank-NP20-
HER 90.3±3.3 88.2±5.1 85.3±4.8 80.3±6.6 78.7±5.2 75.3±4.3 
Taxotere® 56.9±2.6 61.3±1.9 51.3±4.3 57.8±2.1 43.2±3.6 41.4±1.4 
NP20 55.8±3.1 62.7±2.8 43.2±3.0 51.9±6.1 15.6±3.4 16.4±3.2 






















Figure 4-9 In vitro viability of (a) MCF-7 cells and (b) SK-BR-3 cells treated with placebo 
NPs (blank-NP20 and blank-NP20-HER, Taxotere and docetaxel-loaded NPs (NP20 and 
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In order to evaluate the targeting effect of NPs with various amount of trastuzumab 
conjugated on NP surface, the in vitro viability of MCF-7 cells and SK-BR-3 cells treated 
with placebo NPs (Blank-NP0, Blank-NP10-HER, Blank-NP20-HER and Blank-NP30-
HER) or docetaxel-loaded NPs (NP0, NP10-HER, NP20-HER and NP33-HER) at 25 
µg/ml docetaxel concentration after 24 h was shown in Figure 4-10. 
 
The first column of each group shows the viability of MCF-7 cells and SK-BR-3 cells 
treated with placebo NPs. It is obvious that the placebo PLA-TPGS NPs (Blank-NP0) 
have high biocompatibility with fractional cytotoxicity as the viability is 97.8±4.4% and 
98.7±2.8% for MCF-7 cells and SK-BR-3 cells, respectively. The viability for placebo 
PLA-TPGS/TPGS-COOH NPs with trastuzumab-functionalization was found to be 
93.4±2.5% (Blank-NP10-HER), 90.3±3.3% (Blank-NP20-HER), 89.0±5.2% (Blank-
NP33-HER) for MCF-7 cells (Figure 4-10a), and 91.4±3.1% (Blank-NP10-HER), 
88.2±5.1% (Blank-NP20-HER), 87.4±6.9% (Blank-NP33-HER) for SK-BR-3 cells 
(Figure 4-10b), respectively. This means the trastuzumab conjugated on NP surface has 
targeting effect on these two cell lines overexpressing HER2. Moreover, the more amount 
of trastuzumab, the lower the cell viability would be achieved, which means by 
controlling the TPGS-COOH ratio in the fabrication process, the targeting effects of 



























Figure 4-10 In vitro viability of (a) MCF-7 cells and (b) SK-BR-3 cells after 24 h 
treatment with placebo or docetaxel-loaded NP0, NP10-HER, NP20-HER and NP33-HER 













































Same trend can be found from the second column of each group, which stands for the 
viability of these two cell lines treated with docetaxel-loaded NPs. For example, the 
viability of MCF-7 cells shown in Figure 4-10a can be found to be 52.2±3.4%, 46.3±2.7% 
and 45.4±5.72% for NP10-HER, NP20-HER and NP33-HER, respectively. Also, the 
viability of SK-BR-3 cells shown in Figure 4-10b can be found to be 44.4±2.2%, 
36.7±1.3% and 32.6±3.9% for NP10-HER, NP20-HER and NP33-HER, respectively. It is 
clearer when judged by cellular mortality after 24 h treatment. It can be found that NP10-
HER is 1.247- and 1.543-fold more effective than NP0 for MCF-7 cells and SK-BR-3 
cells, respectively. Similarly, NP20-HER is 1.401- and 1.421-fold more effective than 
NP0 for MCF-7 cells and SK-BR-3 cells, respectively. NP33-HER is 1.421- and 1.872-
fold more effective than NP0 for MCF-7 cells and SK-BR-3 cells, respectively. The 
targeting effect of trastuzumab-functionalized NPs is more noticeable for SK-BR-3 cells 
than for MCF-7 cells. By controlling the TPGS-COOH ratio in the fabrication process, the 
targeting effects of trastuzumab-functionalized NPs can thus be controlled.   
 
4.4 Conclusions 
In this chapter, a strategy in the design of molecular probe-conjugated NPs of a blend of 
two biodegradable copolymers was developed for targeted chemotherapy. Of the two 
copolymers, one is PLA-TPGS, which has desired hydrophobic-lipophilic balances to 
promote drug EE and cellular adsorption; and the other copolymer, TPGS-COOH, acts as 
a linker molecule promoting the conjugation of molecular probes on the NP surface. The 
in vitro viability data suggested that the trastuzumab-functionalized PLA-PTGS/TPGS-
COOH NP formulation of docetaxel can be more effective than the PLA-PTGS/TPGS-
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COOH NP formulation with no trastuzumab for MCF-7 cells and SK-BR-3 cells after 24, 
48 and 72 h treatment, respectively. The trastuzumab conjugated on NP surface shows 
targeting effect on both cell lines and lower cell viability would be achieved by treated 
with NPs with more amount of trastuzumab on NP surface. This provides a way to 
quantitatively control the targeting effect of trastuzumab-functionalized NPs by 
controlling the TPGS-COOH ratio in the NP fabrication process. The targeting effect of 
trastuzumab functionalization was more noticeable for SK-BR-3 cells, which are of high 




Chapter 5 Conclusions and recommendations 
5.1 Conclusions 
This main purpose of this work study is to develop trastuzumab-functionalized 
nanoparticles of biodegradable polymers for targeted chemotherapy. The first part of this 
work is on paclitaxel-loaded poly(D,L-lactide-co-glycolide)/montmorillonite nanoparticles 
(PLGA/MMT NPs), which were further decorated with trastuzumab through physical 
adhesion for targeted chemotherapy. Such a nanoparticle system for drug delivery is 
multifunctional, which provides a way to formulate anticancer drugs with no use of 
harmful adjuvant, reduces the side effects of the formulated anticancer drug, promotes 
synergistic therapeutic effects, and achieves targeted delivery of the therapy. The 
paclitaxel-loaded PLGA/MMT NPs were prepared by a modified solvent 
extraction/evaporation technique, which were then decorated with trastuzumab. The 
formed NPs were characterized by various state-of-the-art techniques. Both of the 
quantitative and qualitative cellular uptake investigations showed that the Pac-
PLGA/MMT-HER NPs achieved significantly higher cellular uptake efficiency than the 
Pac-PLGA/MMT NPs. The results of in vitro cytotoxicity experiment on SK-BR-3 cells 
further proved the targeting effect of trastuzumab decoration on the PLGA/MMT NPs. 
Judged by IC50 of SK-BR-3 cells after 24 h culture, the therapeutic effects of the Pac-
PLGA/MMT-HER NP formulation could be 12.74 times higher than that of the Pac-
PLGA/MMT NP formulation and 13.11 times higher than Taxol®.  
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The second part of this work is to develop a strategy in the design of molecular probe-
conjugated NPs of a blend of two biodegradable copolymers for targeted chemotherapy. 
One copolymer is poly(lactide)-D-α-tocopheryl polyethylene glycol succinate (PLA-
TPGS), which is of desired hydrophobic-lipophilic balance to promote drug EE and 
cellular adsorption. And the other is carboxyl group-terminated TPGS (TPGS-COOH), 
which acts as a linker molecule promoting the conjugation of trastuzumab on the NP 
surface for targeting. The in vitro viability data suggested that the trastuzumab-
functionalized PLA-PTGS/TPGS-COOH NP formulation of docetaxel was more effective 
than the PLA-PTGS/TPGS-COOH NP formulation with no trastuzumab for MCF-7 cells 
and SK-BR-3 cells after 24, 48 and 72 h treatment, respectively. The trastuzumab 
conjugated on NP surface shows targeting effect on both cell lines and lower cell viability 
would be achieved by treated with NPs with more amount of trastuzumab on NP surface. 
This provides a way to quantitatively control the targeting effect of trastuzumab-
functionalized NPs by controlling the TPGS-COOH ratio in the NP fabrication process. 
The targeting effect of trastuzumab functionalization was more noticeable for SK-BR-3 
cells, which are of high HER2 overexpression than for MCF-7 cells, which are of 
moderate HER2 overexpression. The trastuzumab-functionalized NPs have great potential 
to be applied as targeted therapeutics against the HER2-overexpressing cancer. 
 
5.2 Recommendations 
The NP formulation has great advantages over the drug alone, resulting in higher 
therapeutic effect and reduced side effects for cancer chemotherapy. Therefore, to develop 
multifunctional NPs of desired size with targeting, molecular detection, imaging, therapy 
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delivery and results-reporting is the ultimate goal of chemotherapy. Size and surface 
modification are the two key factors to determine the performance of NPs of 
biodegradable polymers for chemotherapy. Thus, design and surface engineering of 
nanoparticles may become a direction of targeted drug delivery. Meanwhile, to transplant 
different tumor models to animals and then to observe the inhibition effect of 
biodegradable nanoparticles are important in evaluating the in vivo antitumor ability. 
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